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Foreword
On behalf of the National Hepatitis C Database Steering Committee, I am delighted to introduce the 
2010 report of the National Hepatitis C Database. The Steering Committee oversees the management 
and development of the database and I would like to thank most sincerely Dr Lelia Thornton and her 
team in the HSE Health Protection Surveillance Centre for their continuing commitment and dedication in 
developing and managing the database. 
The database will provide an invaluable resource to researchers, clinicians and to those involved in 
planning future service provision for people who are infected with hepatitis C through contaminated 
blood and blood products. We would like to thank everyone who has given their consent to be included 
in the database and to thank those who actively encourage participation through the hepatology units and 
the hepatitis C patient support groups. Without this participation and co-operation, the gathering of this 
valuable information would not be possible.
This report is based on information collected during 2008 and describes the main findings from these 
data. Over three quarters of those known to have been infected with hepatitis C through contaminated 
blood and blood products are now participating in the database. The continuing collection of their data 
provides very useful information on disease progression and the impact of treatment. There are ongoing 
efforts to improve participation rates and the quality of the data collected. This is especially important at 
this time given that the participants have been infected for an average of 30 years and most are now aged 
over 50, so following the progress of their disease now is crucial.
Some important information which is now being presented to us through the database includes data 
relating to numbers of people with signs of serious liver disease. The majority of participants in the 
database, including those chronically infected, do not show evidence of having serious liver disease. We 
have also learned that those participants with high alcohol intake have almost five times higher odds of 
having serious liver disease than those without. Another valuable piece of information coming from the 
database is the high success rates of treatment amongst the Irish population. We also know that the 
majority of those chronically infected do continue to attend their hepatology unit regularly and also to 
avail of other out-patient services, all of which are provided without charge under the terms of the Health 
(Amendment) Act 1996.
The National Hepatitis C Database Steering Committee looks forward to continuing to work with the 
project and to the ongoing learning which is emerging.
Michele Tait
Chair, 
National Hepatitis C Database Steering Committee
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Executive Summary
Hepatitis C infection is a major cause of liver disease and it is estimated that up to 20% of people 
with chronic infection will develop cirrhosis over a 20 to 25 year period. Very effective treatment 
is now available, which eradicates the virus in over 50% of cases. 
Approximately 1,700 people in Ireland became infected with hepatitis C virus (HCV) through 
contaminated blood and blood products. The National Hepatitis C Database was established to 
gather information on people infected in this way. This report describes the results of the third 
round of data collection.
Main findings
Profile of participants
•Twentyeightpeoplehavebeenaddedtothedatabasesincethelastroundofdatacollection.
The total number of participants is 1,303 (76% of those eligible).
•Olderpeopleweremorelikelytoparticipateinthedatabase.
•Themajorityofdatabaseparticipantswereinfectedthroughcontaminatedanti-D
immunoglobulin (62%), with 26% infected through receipt of blood transfusions or treatment for 
renal disease, and 12% through blood clotting factors.
•73%ofthedatabasepopulationarefemales,reflectingthelargeanti-Dcohort.
•Theaverageageofthedatabasepopulationisnow57yearsandtheaveragedurationof
infection is 30 years. These figures vary by source of infection:
o The larger anti-D cohort (1977-79 outbreak) have an average age of 58 years and 
duration of infection of 31 years.
o The smaller anti-D cohort (1991-94 outbreak) have an average age of 45 years and 
duration of infection of 15 years.
o The blood transfusion/renal group have an average age of 60 years and duration 
of infection of 23 years.
o The blood clotting factor group have an average age of 44.5 years and duration 
of infection of 31 years.
Hepatitis C status
•Overall,62%ofparticipantshadtestedHCVRNApositive(indicatingactiveinfection)atleast
once, and a further 15% had positive HCV confirmatory antibody tests but no positive RNA 
results. The remaining 23% tested either ELISA/EIA (screening test) positive/weak positive or 
had an indeterminate result on confirmatory testing.
•Thetrueviralclearancerateforparticipantsislikelytobebetween19%and36%(havingtaken
account of those who died before RNA testing, and allowing for the possibility that some 
participants may have had false positive screening test results).
•Femalesweresignificantlymorelikelytohaveclearedthevirusatthetimeofdiagnosis.
•76%wereHCVgenotype1and19%genotype3.
Alcohol consumption
•Informationaboutalcoholconsumptionwasinfrequentlyrecorded.However,alcoholintakein
excess of the recommended limits (for the general population) was recorded in the medical 
- 6 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
notes of 15% of chronically infected participants where data were available; this was more common in 
males (32%) than females (9%).
Outcomes
The overall impression from this latest round of data collection is that, although there is evidence of 
progression of disease in some people, the majority of the database population, even those chronically 
infected, do not have any evidence of serious liver disease.
In the absence of a population-based comparison group, we have compared chronically infected database 
participants (ever RNA positive) with those who never became chronically infected, in the reporting of 
most medical outcomes.
•Depression,hypertension,fibromyalgia/myalgia,dermatitis,diabetes,osteoporosis,andgastro-
oesophageal reflux were all recorded significantly more often for those chronically infected than those 
who were never chronically infected.
•Elevatedalanineaminotransferase(ALT)levelswereassociatedwithchronicinfection,malegender,high
alcohol consumption and being infected for more than 30 years.
•Cirrhosishaddevelopedinfourteenpercentofthosewithchronicinfectionandinnonewhodidnot
have chronic infection.
•TheaveragedurationofbeingRNApositiveattheestimateddateofcirrhosiswas21yearsandthe
average age at cirrhosis was 51 years.
•Thenumberofparticipantswithcirrhosishasincreasedby19sincethelastroundofdatacollection.
•AfterRNAstatus,alcoholintakewasthebiggestdeterminantofriskofcirrhosis.
•Malegenderandolderageatlatestfollow-upwereindependentriskfactorsforcirrhosis.Thoseinfected
through transfusion/renal treatment or through blood clotting factors were significantly more likely to 
have developed cirrhosis.
•Thenumberofparticipantswithhepatocellularcarcinoma(HCC)hasincreasedbythree,givingatotalof
23 (3%).
•TheaveragedurationofinfectionattheestimateddateofHCCwas25yearsandtheaverageageat
HCC was 63 years.
•Twentyfivepercentofchronicallyinfectedparticipantshadmoderateorsevereinflammationonlast
biopsy compared to 1% of participants who were never chronically infected.
•Nineteenpercentofchronicallyinfectedparticipantshadahighfibrosisscore(includingcirrhosis)on
their most recent biopsy compared to 4% of those who did not have chronic infection.
•Theaverageageatthefirsthighfibrosisscorewas51yearsandtheaveragedurationofinfectionwas
19 years.
•Ahighfibrosisscore(includingcirrhosis)wasassociatedwithhighalcoholintake,olderageatbiopsy,
longer duration of infection, male gender, infection through blood transfusion or renal treatment, and 
genotype 3 infection.
•Onehundredandeightyeightparticipantshaddied,anadditional15sincethelastroundofdata
collection.
•Mortalityrateswerehigherinchronicallyinfectedparticipants(16%)comparedtothosewhowerenever
chronically infected (4%), and were also higher in those infected through blood transfusions or clotting 
factors, those who had high alcohol intake and those who were older at the time of infection.
•Liver-relatedmortalityoccurredin48participants,andwashigherinchronicallyinfectedparticipants,
those with high alcohol intake, males, those infected through blood transfusion or clotting factors, and 
participants who were older when infected.
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•Forchronicallyinfectedparticipantstherehasbeenasmallbutclearprogressionintheprevalenceofall
liver-related outcome measures since baseline data collection about three years ago.
•Asummarymeasurewasdevelopedtoclassifyparticipantsashavingsevere,moderateormild/noliver
disease (described on page 38). Of chronically infected participants, 27%, 20% and 53% were classified 
as having severe, moderate and mild/no liver disease respectively, compared to 2%, 1% and 97% of 
those who never became chronically infected.
•Thedeterminantsofhavingsevereliverdiseasewerehighalcoholintake,olderageatfollow-up,male
gender, longer duration of being RNA positive, and HCV genotype 3.
•Participantswhohadhighalcoholintakehadalmostfivetimeshigheroddsofhavingseveredisease
than those without.
•Eighteendatabaseparticipantshadreceivedlivertransplants,atanaverageageof52.5yearsandan
average duration of HCV infection of 28.5 years. Where post-transplant information was available, most 
showed accelerated disease progression.
Anti-viral treatment
•Almost41%ofchronicallyinfectedparticipantshadreceivedatleastonecourseofanti-viraltreatment.
Those with HCV genotype 2 or 3 were more likely to have been treated (68% and 70% respectively) than 
those with genotype 1 (33%).
•Twentyfourpercentofalltreatmentcourseswerestoppedearlyduetosideeffects.
•Treatmentnaïveparticipantsoncombinationtherapyfor48weeksormoreachievedasustained
virological response (SVR) in 77% of genotype 2 or 3 cases and in 47% of genotype 1. 
•OtherfactorsassociatedwithSVRincludedyoungerageattreatment,femalegender,andlowerfibrosis
score.
•ParticipantsinfectedthroughclottingfactorswerelesslikelytoachieveSVR.
Focus on the different patient groups
Participants infected through anti-D immunoglobulin
•Thisgrouphadthelowestprevalenceofseriousliver-relatedoutcomes.
•Nineteenpercentwereclassifiedashavingsevereliverdisease.
•Ninepercenthaddevelopedcirrhosis.
•Therelativelylowlevelofdiseaseprogressioninthisgroupisprobablyattributabletothefactthatthey
are female, were infected at a young age and have lower prevalence of high alcohol intake (4%).
•The1977-79outbreakgroup(genotype1)havealowuptakeofanti-viraltreatment(27%)andalow
overall SVR on last treatment, compared with treatment uptake of 89% for the 1991-1994 outbreak 
group (genotype 3), who had an overall SVR on last treatment of 90%.
Participants infected through blood transfusion/renal treatment
•Thisgrouphadthehighestrateofchronicinfection,82%,attimeofdiagnosis.
•Theyalsohadthehighestprevalenceofsevereliverdiseaseat38%.
•Twentytwopercenthaddevelopedcirrhosis.
•Thesefindingsmaybeexplainedbythefactthatmanyofthisgrouphadco-morbiditiesandmany
became infected with HCV as a result of treatment for serious conditions. They were also slightly older 
at the time of infection and had a higher prevalence of high alcohol intake (13%).
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Participants infected through blood clotting factors
•Thirtyonepercentwereclassifiedashavingsevereliverdisease.
•Fourteenpercentwerediagnosedashavingcirrhosis.
•Thesefindingsmaybepartlyexplainedbythefactthatmostofthisgrouparemale,17%werereported
as having a high alcohol intake, and 42% were co-infected with HIV.
•FortyonepercenthadreceivedcombinationtreatmentforHCVandtheSVRrateswerenotstatistically
worse in the HIV co-infected participants than in those who were mono-infected, and were comparable 
to those achieved by participants infected through other means. However, numbers were low.
Clinical management
•Theproportionofchronicallyinfectedparticipantstakinglong-termmedicationstotreatdepression,
anxiety or diabetes was significantly higher than for those not chronically infected.
•Seventysevenpercentofalllivingdatabaseparticipantshadattendedtheirhepatologyunitin2007or
2008, this figure being higher for those chronically infected (88%).
•Twentytwopercentofchronicallyinfectedparticipantsand11%ofthoseneverchronicallyinfectedhad
visited the hospital on an in-patient basis since last follow-up.
•Thespecialisthospitalservices,otherthanhepatology,mostcommonlyattendedbychronicallyinfected
participants were haematology, psychiatry/psychology/counselling, endocrinology and rheumatology.
•Informationontheuseofcomplementaryandalternativetherapiesisrecordedinthedatabase,
whenever it is available in the medical charts. However, this is not likely to be a reliable source of this 
information. Information on the use of these therapies has been gathered by a separate health and 
lifestyle survey which will be published shortly.
Conclusion
The National Hepatitis C Database project has progressed in both participation rate and quality of data 
since its establishment six years ago. The ongoing support of participants, support groups and health 
professionals is essential to its success. Eligible people who have not yet participated may join at any time 
through their hepatology unit.
We would encourage hepatology unit staff to record body weight/BMI and alcohol consumption 
information as a routine at clinic visits. In the next round of data collection, additional information, 
where available, will be collected on: insulin resistance, steatosis, fibroscans, details of adverse effects of 
treatment, both starting and finishing treatment doses, and clinic follow-up/discharge status of patients. 
We also look forward to carrying out more detailed analysis of viral load data.
The data in the database are available for use by researchers and by the participating hepatology units. 
We welcome any comments and suggestions that participants, health professionals or other interested 
people may have on ways in which we could improve the database and the use of the information 
contained in it.
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Table 1. Summary of main outcomes by hepatitis C RNA status for all participants
Outcomes All
Ever chronically 
infected *
Never chronically 
infected † 
No RNA results in 
chart
 Number % Number % Number % Number %
Signs of liver disease 167 12.8 155 19.2 5 1.1 7 14.0
Cirrhosis 116 8.9 111 13.8 0 0.0 5 10.0
Liver tumours or HCC 25 1.9 23 2.9 0 0.0 2 4.0
 High fibrosis score on 
biopsy ‡
161 12.4 154 19.1 4 0.9 3 6.0
Deceased 188 14.4 129 16.0 18 4.0 41 82.0
 Liver related disease directly 
caused death § 
48 3.7 38 4.8 2 0.5 8 17.4
All 1303  806  447  50  
*  At least one positive hepatitis C RNA result – testing carried out some time after infection so this is a good indicator of chronic 
infection
†  Positive or indeterminate line-immunoassay results (RIBA/INNO-LIA) or positive/weak positive EIA/ELISA results, RNA tests done 
but never tested RNA positive. These participants cleared the hepatitis C virus spontaneously and are likely to have done so within a 
year of infection
‡  Ever had a fibrosis score of 3 or 4 on biopsy scored from 0 to 4 or a fibrosis score of 4, 5 or 6 on biopsy scored from 0 to 6. The 
proportion of chronically infected participants who had biopsies was significantly higher than that for participants who did not 
become chronically infected
§  Denominator for this is all participants minus those whose cause of death was not available (n=1289)
Table 2. Current RNA status (this includes the last known status of deceased participants) for all 
participants
Final status All Ever chronically infected*
 Number % Number %
Currently chronically infected † 612 48.8 612 75.9
Treated and cleared virus 161 12.9 161 20.0
Cleared virus without treatment ‡ 480 38.3 33 4.1
Had positive confirmatory antibody results § 223 17.8 33 4.1
Not confirmed positive|| 257 20.5   
All 1253 100 806 100
* At least one positive hepatitis C RNA result 
† Hepatitis C RNA positive at most recent test (includes participants who have died)
‡ Hepatitis C antibody positive, never treated
§ Positive line-immunoassay results (RIBA/INNO-LIA) results
||   positive/weak positive EIA/ELISA results or indeterminate line-immunoassay results, RNA tests done but never tested RNA positive.
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status 
(n=50)
Summary tables
- 10 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
Table 3. Summary of main outcomes by hepatitis C RNA status for all anti-D participants
Outcomes All*
Ever chronically 
infected
Never chronically 
infected
 Number % Number % Number %
Signs of liver disease 53 6.6 49 11.4 3 0.8
Cirrhosis 39 4.9 38 8.8 0 0.0
Liver tumours or HCC 3 0.4 3 0.7 0 0.0
High fibrosis score on biopsy 72 9.0 69 16.1 2 0.6
Deceased 43 5.4 31 7.2 11 3.0
Liver related disease directly caused death † 8 1.0 6 1.4 1 0.3
All 803  430  363  
*  There were no RNA results in the charts of 10 participants. These are included under all, but not under ever or never chronically 
infected
†  Denominator for this is all participants minus those whose cause of death was not available (n=797)
Table 4. Current RNA status (this includes the last known status of deceased participants) for all 
anti-D participants
Final status All Ever chronically infected
 Number % Number %
Currently chronically infected 342 43.1 342 79.5
Treated and cleared virus 67 8.5 67 15.6
Cleared virus without treatment 384 48.4 21 4.9
Had positive confirmatory antibody results 167 21.1 21 4.9
Not confirmed positive 217 27.4   
All 793 100 430 100
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status 
(n=10)
Table 5. Summary of main outcomes by hepatitis C RNA status for anti-D participants infected 
between 1977 and 1979 
Outcomes All*
Ever chronically 
infected
Never chronically 
infected 
 Number % Number % Number %
Signs of liver disease 49 7.3 45 12.0 3 1.0
Cirrhosis 36 5.3 35 9.3 0 0.0
Liver tumours or HCC 3 0.4 3 0.8 0 0.0
High fibrosis score on biopsy 69 10.2 66 17.6 2 0.7
Deceased 42 6.2 30 8.0 11 3.8
 Liver related disease directly caused death † 8 1.2 6 1.6 1 0.3
All 675  376  293  
*  There were no RNA results in the charts of 6 participants. These are included under all, but not under ever or never chronically 
infected
†  Denominator for this is all participants minus those whose cause of death was not available (n=670)
Note: One participant who was infected during this anti-D outbreak period had a non-outbreak genotype and was excluded from this 
table
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Table 6. Current RNA status (this includes the last known status of deceased participants) for anti-D 
participants infected between 1977 and 1979
Final status All Ever chronically infected
 Number % Number %
Currently chronically infected 325 48.6 325 86.4
Treated and cleared virus 33 4.9 33 8.8
Cleared virus without treatment 311 46.5 18 4.8
Had positive confirmatory antibody results 154 23.0 18 4.8
Not confirmed positive 157 23.5   
All 669 100 376 100
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status 
(n=6). One participant who was infected during this anti-D outbreak period had a non-outbreak genotype and was also excluded from 
this table
Table 7. Summary of main outcomes by hepatitis C RNA status for anti-D participants infected 
between 1991 and 1994
Outcomes All*
Ever chronically 
infected
Never chronically 
infected
 Number % Number % Number %
Signs of liver disease 3 4.2 3 8.1 0 0.0
Cirrhosis 2 2.8 2 5.4 0 0.0
Liver tumours or HCC 0 0.0 0 0.0 0 0.0
High fibrosis score on biopsy 2 2.8 2 5.4 0 0.0
Deceased 0 0.0 0 0.0 0 0.0
Liver related disease directly caused death 0 0.0 0 0.0 0 0.0
All 72  37  31  
*  There were no RNA results in the charts of 4 participants. These are included under all, but not under ever or never chronically 
infected
Note: 5 participants who were infected during this anti-D outbreak period had non-outbreak genotypes and were excluded from this 
table
Table 8. Current RNA status (this includes the last known status of deceased participants) for anti-D 
participants infected between 1991 and 1994
Final status All Ever chronically infected
 Number % Number %
Currently chronically infected 6 8.8 6 16.2
Treated and cleared virus 29 42.7 29 78.4
Cleared virus without treatment 33 48.5 2 5.4
Had positive confirmatory antibody results 6 8.8 2 5.4
Not confirmed positive 27 39.7   
All 68 100 37 100
*Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status (n=4). 
Five participants who were infected during this anti-D outbreak period had non-outbreak genotypes and were also excluded from this 
table
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Table 9. Summary of main outcomes by hepatitis C RNA status for blood transfusion/renal 
participants
Outcomes All*
Ever chronically 
infected
Never chronically 
infected
 Number % Number % Number %
Signs of liver disease 79 23.7 76 28.3 2 3.3
Cirrhosis 59 17.7 58 21.6 0 0.0
Liver tumours or HCC 15 4.5 15 5.6 0 0.0
High fibrosis score on biopsy 80 24.0 76 28.3 2 3.3
Deceased 77 23.1 68 25.3 6 9.8
Liver related disease directly caused death † 21 6.4 20 7.5 1 1.6
All 333  269  61  
*  There were no RNA results in the charts of 3 participants (all deceased). These are included under all, but not under ever or never 
chronically infected
†  Denominator for this is all participants minus those whose cause of death was not available (n=329)
Table 10. Current RNA status (this includes the last known status of deceased participants) for blood 
transfusion/renal participants
Final status All Ever chronically infected
 Number % Number %
Currently chronically infected 195 59.1 195 72.5
Treated and cleared virus 67 20.3 67 24.9
Cleared virus without treatment 68 20.6 7 2.6
Had positive confirmatory antibody results 33 10.0 7 2.6
Not confirmed positive 35 10.6   
All 330 100 269 100
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status 
(n=3)
Table 11. Summary of main outcomes by hepatitis C RNA status for blood clotting factor participants
Outcomes All
Ever chronically 
infected
Never 
chronically 
infected
No RNA results in 
chart
 Number % Number % Number % Number %
Signs of liver disease 34 21.1 29 27.9 0 0.0 5 13.5
Cirrhosis 17 10.6 14 13.5 0 0.0 3 8.1
Liver tumours or HCC 7 4.4 5 4.8 0 0.0 2 5.4
High fibrosis score on biopsy 9 5.6 9 8.7 0 0.0 0 0.0
Deceased 67 41.6 29 27.9 1 5.0 37 100.0
 Liver related disease directly caused 
death *
18 11.5 11 10.7 0 0.0 7 20.6
All 161  104  20  37  
* Denominator for this is all participants minus those whose cause of death was not available (n=157)
- 13 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
Table 12. Current RNA status (this includes the last known status of deceased participants) for blood 
clotting factor participants
Final status All Ever chronically infected
 Number % Number %
Currently chronically infected 72 58.1 72 69.2
Treated and cleared virus 27 21.8 27 26.0
Cleared virus without treatment 25 20.2 5 4.8
Had positive confirmatory antibody results 21 16.9 5 4.8
Not confirmed positive 4 3.2   
All 124 100 104 100
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status 
(n=37)
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Hepatitis C RNA status and disease outcomes
% of eligible
people
participating
in the
database
% of
participants
with RNA
results who
ever tested
RNA positive
Liver related
outcomes for
participants
who ever tested
RNA positive
Liver related
outcomes for
participants
who had RNA
results in their
charts but never
tested RNA
positive
Number of
database
participants
1303 803 333 161
All parcipants An-D Transfusion/ renal Clong factors
76.0 75.5 80.8 73.2
All parcipants An-D Transfusion/ renal Clong factors
64.3 54.2 81.5 83.9
All parcipants An-D Transfusion/ renal Clong factors
19.2
11.4
28.3 27.9
13.8
8.8
21.6
13.5
2.9
0.7
5.6 4.84.8
1.4
7.5
10.7
All parcipants An-D Transfusion or renal Clong factors
% with serious signs of liver disease % with cirrhosis
% with HCC % who have died from liver related causes
1.1 0.8
3.3
00 0 0 00 0 0 00.5 0.3 1.6 0
All parcipants An-D Transfusion or renal Clong factors
% with serious signs of liver disease % with cirrhosis
% with HCC % who have died from liver related causes
Figure 1. Summary of RNA status, and disease progression by RNA status, for all participants and by 
source of infection  
Note: 50 participants had no RNA results in their charts. Of these, 37 were infected through contaminated blood clotting factors. 
These participants were similar to the participants who became chronically infected in terms of outcomes. Six participants had a 
source of infection other than those shown.
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Chronic hepatitis C infection is a major cause of chronic liver disease and death throughout the world.1 
Approximately 3% of the world’s population is infected with hepatitis C virus (HCV).2 Hepatitis C infection 
is caused by an RNA virus that was first identified in 1989.3 Six distinct but related genotypes and multiple 
subtypes have been identified. In Western Europe genotypes 1a and 1b are most common, followed by 
genotypes 2 and 3.4
HCV is transmitted by blood and now occurs primarily through injecting drug use, and less frequently 
through sex with an infected partner, occupational exposure, and maternal-fetal transmission. In 
some cases no risk factors can be identified.4,5 Transfusion-related HCV infection is rare now since the 
introduction of routine screening of blood for HCV antibodies in the early 1990s.
Acute HCV infection, in general, is relatively mild with only 20-30% of infected persons developing 
symptoms or clinically evident acute infection.2 In most persons who become infected with HCV, viraemia 
persists. Chronic HCV infection is marked by persistence of HCV RNA for at least 6 months after onset 
of infection. Spontaneous resolution after 6 or 12 months of infection is unusual.3 Between 55 and 85% 
of those infected develop chronic infection6, the lower end of the range being accounted for mainly by 
women, particularly young women.7,8
Chronically infected people are at risk for progressive liver disease characterised by hepatocellular 
inflammation, hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC).6 These complications develop 
only in a proportion of patients and only after many years or decades of infection.3 It has been estimated 
that up to 20% of chronically infected individuals will develop cirrhosis of the liver over a 20 to 25 year 
period, and that, of patients with cirrhosis, approximately 3% to 4% will develop HCC per year.9 Factors 
that have been shown to be associated with progression of liver fibrosis include older age at infection, 
male gender, genetic factors, metabolic factors (steatosis, diabetes and obesity), co-infection with human 
immunodeficiency virus (HIV) or hepatitis B, duration of infection, and alcohol intake.1,4,6,9
Chronic HCV infection has been associated with several extrahepatic manifestations including essential 
mixed cryoglobulinemia, B-cell non-Hodgkin lymphoma, glomerulonephritis, seronegative arthritis, 
keratoconjunctivitis sicca and sialadenitis, lichen planus, neuropathies and neurological conditions including 
cognitive disorders and porphyria cutanea tarda.3
Very effective treatment is now available, which eradicates the virus in over 50% of cases.1,10,11 Genotype 
and serum viral load are useful predictors of response to treatment. Response rates to treatment by 
pegylated interferon and ribavirin combination are more than 75% for genotypes 2 and 3, and 40-50% for 
genotype 1.
Chapter 1  Hepatitis C Virus Infection
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Hepatitis C infection
Hepatitis C natural history
Chronic infection
 (55-85%)
Hepatitis C RNA still
detectable. Long-term
hepatitis C infection
Liver fibrosis
Acute infection
followed by viral
clearance
(15-45%)
Hepatitis C RNA no
longer detectable.
6 months
Cirrhosis of the
liver
Liver failure or
hepatocellular
carcinoma
Mild
Moderate
Advanced
20 - 40 years
Factors increasing rate of disease
progression and disease severity
High alcohol consumption
High BMI, insulin resistance or
steatohepatitis
Male gender
Older age
Co-infection with HIV
Co-infection with hepatitis B
Factors decreasing or halting disease
progression and disease severity
No or low alcohol consumption
Healthy BMI
Anti-viral treatment
Liver transplant (temporary)
Limited or no long-
term effects
At risk for
Figure 2. Summary of natural history of hepatitis C infection
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Background to the database
Approximately 1,700 people have been identified as being infected with HCV through the receipt 
of contaminated blood and blood products in Ireland. These include women infected through anti-D 
immunoglobulin, recipients of blood transfusion, people with haemophilia and other blood clotting 
disorders and people who received treatment for renal disease.12 Specialist hepatology services were set 
up in eight designated hospitals to provide services for this group. Those infected are also entitled to a 
range of additional hospital and primary care services under the Health (Amendment) Act, 1996 (HAA). 
Many of these people have a known year of infection and a large proportion has now been infected for 
over 25 years. 
The National Hepatitis C Database for infection acquired through blood and blood products was set up 
by the Health Protection Surveillance Centre (HPSC) in association with the eight specialist hepatology 
units and is supported financially by the Health Service Executive (HSE) and formerly by the Department 
of Health and Children (DoHC). Approval for this project was obtained from the ethics committees of 
all eight hospitals and from the Office of the Data Protection Commissioner. The development and 
management of the database project is overseen by a steering committee (appendix A). A scientific and 
technical group supports and advises HPSC on the scientific and technical development of the database 
(appendix B).
The objectives of the database are: 
1. To follow the natural history of infection in people infected through blood and blood products
2. To evaluate the impact of various host factors on the progression of the disease
3. To evaluate the outcomes of treatment
4. To monitor the uptake of services
5. To provide information for the planning and evaluation of health services
6. To serve as a resource for future research into hepatitis C
Baseline data were collected in 2005 and 2006 and included all relevant data from the date of diagnosis 
on all consented participants. A report describing these data was published in October 2007.13 A report 
on the first round of follow-up data was published in February 2009.14 This is currently the second round 
of follow-up data collection and includes information on all participants up to the end of 2008. All reports 
and patient newsletters are available through the hepatology units, patient support groups, hepatitis C 
liaison officers and on the database website (www.hcvdatabase.ie).
Database population
Any person (alive or dead) who contracted HCV infection through the administration of blood or blood 
products within the state is eligible to be included in the database. These include women infected through 
anti-D immunoglobulin, recipients of blood transfusion, people with haemophilia and other blood clotting 
disorders and people who received treatment for renal disease. Eligible patients were identified by the 
eight specialist hepatology units.13
 
For the purpose of this database, hepatitis C infection is defined as the detection of hepatitis C specific 
antibodies or the detection of hepatitis C nucleic acid. This includes all those who are ELISA (enzyme 
linked immunosorbent assay)/EIA (enzyme immunoassay) positive or weak positive, recombinant 
immunoblot assay (RIBA)/INNO-LIA positive or indeterminate, or hepatitis C polymerase chain reaction 
(PCR)/RNA positive. 
Chapter 2  National Hepatitis C Database
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Information is collected only on eligible people who consent to participate in the database and on eligible 
participants who have died. Relatives of deceased people are entitled to refuse participation and no data 
are collected on those who refused to participate in the database when they were alive. 
Source of data
Information is gathered from the participants’ medical records (hospital charts) in the eight hepatology 
units and is updated on an annual basis. No direct contact is made with any participant. No names or 
addresses are recorded in the database. 
Data security
The database was built using MS SQL server 2000. It is physically located in a secure computer room in 
HPSC with access strictly limited to key technical support staff. Access to the database is secured by a 
combination of network, SQL server and MS Access security permissions. All paper forms are stored in a 
locked cabinet in HPSC. 
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Chapter 3 Follow-up Data Collection to 
end 2008 
Data Collection
Data collection is carried out annually on participants in the database. This second round of follow-up 
data collection began in January 2008. The data collection form used is shown in appendix C. Data are 
extracted from the participants’ medical notes by a HPSC research nurse. The follow-up data collected 
include all new clinical, demographic and lifestyle data added to the participants’ medical records 
between the date of last data collection and the date of follow-up data collection (up to 31st December 
2008). Data were entered into the database by a surveillance assistant. Double entry was used to 
maximise accuracy. 
In order to improve the information held on participants, some additional data have been requested on 
the latest follow-up data collection form. Information regarding glucose tolerance testing, current hepatitis 
B status and fibroscan results have now been added to the follow-up form.
Recruitment of new participants 
Recruitment of new participants to the database is ongoing and new participants are welcome to join 
at any time. These would include those people who did not consent to database participation when 
first invited to do so in 2004, and those newly identified as eligible since 2004. Patients are given the 
opportunity to consent at their hospital appointments where they are given further information about 
the database by staff. This has proven to be a successful method of encouraging patients who have not 
yet consented to consider participating in the database. Those who refused to consent at any time are 
not asked again. The patient support groups also encourage their members to participate through their 
newsletters and meetings.
There is a small number of people living abroad (approximately 25, personal communication, Michelle Tait 
HSE), who meet the eligibility criteria for the database but who do not attend a clinical service in Ireland. 
They are not currently included in the database due to the difficulties that would arise in terms of data 
collection, data quality, confidentiality and consent.
Assumptions
Various assumptions were made where data were missing. These related mainly to the year of infection. 
These assumptions were:
•Anti-D:Ifthepersonhadreceivedanti-Donmultipleoccasions,andoneofthesewastheyearofan
outbreak period, i.e. 1977-1979 or 1991-1994, this year was taken as the year of infection. If none of 
the years fell into either of the outbreak periods, the earliest year that anti-D had been administered 
was used as the year of infection.
•Bloodtransfusion/treatmentforrenaldisease:Ifthepersonhadreceivedmultiplebloodtransfusions
and none of them had been identified as being infectious, the earliest transfusion year was taken as the 
year of infection. Where the person had also been on dialysis for extended periods of time, the year of 
starting dialysis or of first blood transfusion, whichever was the earlier, was used as an estimate of the 
year of infection.
•Clottingfactors:Forpeoplewithhaemophiliaandotherbloodclottingdisorders,iftheyearofinfection
was not available, the year that the patient first received clotting factors was used as a proxy for the 
year of infection. Where the year of infection and the year when first factor was administered were 
missing, then the year of diagnosis of haemophilia was used as the year of infection. 
•Whereprecisedayormonthweremissingfromdates(e.g.dateofinfection),theyearofinfectionwas
converted to 02/07/YYYY, where YYYY was the year of infection and 02/07 was the midpoint of the 
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year. All ages calculated were truncated and all durations were rounded based on the outcome of the 
calculation. 
Estimating dates of cirrhosis and hepatocellular carcinoma (HCC)/liver cancer
Variables were created to indicate if participants had cirrhosis or liver cancer on biopsy or mentioned 
elsewhere in their medical charts or death certificates. Estimated dates of onset were generated for both 
conditions, but these were approximate. If multiple biopsies, ultrasounds or CT scans were done, the 
midpoint between the first positive and last negative date was used. Where cirrhosis or liver cancer was 
first mentioned on death certificates, the midpoint between the date of death and last negative diagnostic 
test or last visit to the hepatology unit was used. Otherwise the earliest date mentioned in relation to a 
diagnosis of cirrhosis or liver cancer was taken.
Estimating duration of hepatitis C ribonucleic acid (RNA) positivity
All RNA results were recorded for each participant. A variable was created to record the duration of RNA 
positivity in years for all participants who ever tested RNA positive. The following rules were used:
•IfaparticipantremainedRNApositivewhenlasttestedandwasstillalive,thedurationofRNA
positivity was calculated as their date of last visit minus their date of infection. If they were deceased, 
their date of death minus their date of infection was used.
•ForparticipantswhohadtestedRNApositiveandclearedthevirus,thedurationofRNApositivity
was calculated as the midpoint between the first negative and last positive result minus their date of 
infection.
Coding of death certificates
Death certificates were collected on deceased participants from the General Register Office (GRO). This 
was done by the research nurse, acting on behalf of the hepatology unit. No named data were brought to 
HPSC. The cause of death was coded using the World Health Organization (WHO) ICD-10 coding format. 
Analysis was done on the underlying cause of death as defined by the ICD system. 
The cause of death was further classified using the following broad categories:
•Deathdirectlycausedbyliver-relateddisease
•Deathnotdirectlycausedbyliver-relateddisease,butliverdiseaseorhepatitisClistedasa
contributing condition on the death certificate
•Deathwasnotliver-related
Death was considered to be directly caused by liver-related disease in the following situations:
If hepatocellular carcinoma or end-stage liver disease (varices, ascites, liver failure or hepatic 
encephalopathy) were listed as any of the causes of death in section I of the death certificate
Or if liver disease was not specified as end-stage (e.g. cirrhosis) but the sequence of causes of death on 
the certificate suggested death was due to liver disease, 
Or if liver disease was coded as the underlying and only cause of death.
The classification of all deaths was carried out by a consultant hepatologist and a medical epidemiologist, 
blinded to the hepatitis C immunoblot or RNA status.
Long-term medications
Long-term medications mentioned in the patient’s chart are recorded in the database and were coded 
using the Anatomical Therapeutic Chemical (ATC) classification system. This is a standardised coding 
system, controlled by the World Health Organization, and is based on the organ or system on which the 
drug acts. 
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Liver biopsies
Different scoring systems were used to stage and grade the hepatitis C liver biopsies in the different 
hepatology units (appendix D):
•Knodellsystem:15 fibrosis scored from 0-4 
•ModifiedKnodellsystem,16,17 also known as the Ishak or the modified HAI system: fibrosis 
scored from 0-6 
•Scheuersystem:18 fibrosis scored from 0-4
•InternationalGroupofHepatopathologistssystem:fibrosisscoredfrom0-4
For some of the analyses, the biopsies scored from 0 to 6 were converted to 0 to 4 scores so that all 
scored biopsies could be considered together. The following conversions were used: 0=0, 1=1, 2=1, 3=2, 
4=3, 5=3 and 6=4. 
 
Data analysis
Data analysis was done using Business Objects, Microsoft Access 2007, Microsoft Excel 2007 and Stata/SE 
version 10.0. Either Pearson’s Chi-square or the Wald test, with corresponding probability value (P-value) 
and 95% confidence intervals, were used to test for differences between odds of a given outcome in 
logistic regression analysis. Poisson regression was used to examine survival since infection with HCV. All 
statistical tests were 2-tailed and a p-value of < 0.05 was taken as statistically significant.
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Chapter 4  Main Findings
The main findings of the second round of follow-up data collection are presented as follows:
•Summaryofparticipationratesandrepresentativenessofthedatabasecohort
•Descriptionofdatabasepopulation
o RNA results
o End of latest follow-up
o Age, gender, source of infection, duration of infection and genotype
•Alcoholconsumption
•Outcomes
o Medical conditions
o Liver function tests – alanine amino transferase (ALT)
o Signs of serious liver disease, cirrhosis and hepatocellular carcinoma
o Biopsy results
o Deceased participants
•Changesintheprevalenceofthemainoutcomessincebaselinedatawerecollected
•Summaryofdiseaseprogressionandthefactorsassociatedwithdiseaseseverity
•Anti-viraltreatmentforhepatitisC
•Livertransplants
•Focusonthedifferentpatientgroups
•Clinicalmanagementandhealthserviceusage
o Long term medications other than anti-viral treatment 
o Visits to the hepatology unit
o Specialist health services and procedures
o Complementary and alternative therapies
Summary of participation rates and representativeness of the database 
cohort
New participants
Twenty eight people have been added to the database since the first round of follow-up data collection, 
bringing the total number of participants to 1,303. The new database participants include twenty five 
new consents and three people who are newly deceased or newly identified as deceased. The overall 
participation rate is now 76%, including people who have died, and the consent rate is 74% (figure 3).
Sixty two percent (n=803) of database participants were infected with HCV through contaminated 
anti-D, 26% (n=333) were infected either through receipt of contaminated blood transfusions or through 
treatment for renal disease, 12% (n=161) of participants were infected through contaminated blood 
clotting factors and six participants were infected through sexual or vertical contact with people with 
state-acquired infection.
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Eligible people who died before start of
study
159 (9.3%)
Eligible people who were living when the
study started
 1555 (90.7%)
Consented
1148 (73.8%)
No response
353 (22.7%)
Refused
54 (3.5%)
Overall cohort of people who had consented or had died
1315 (76.7% of total eligible)
Total database cohort
at year 2 of follow up
1303 (76.0%)
Charts missing
  12 (all RIP)
Non responders who died
after the study started
8
Source of infection
Response rates and summary of cohort (n=1714)
Anti-D
n=803, 61.6%
Blood transfusion/treatment for
renal disease
n=333, 25.6%
Blood clotting
factors
n=161, 12.4%
Other
n=6, 0.5%
Figure 3. Summary of participation rates and database cohort
Note: Source of infection = “Other” includes participants infected through vertical or sexual contact with people with state-acquired 
infection
Although we do not have patient-based data on source of infection or gender for non-participants, the 
hepatology units provide us with summary data to enable us to assess how representative the database 
population is of the entire eligible population. 
The proportion of patients infected through blood transfusions who were included in the database 
was higher than the proportions of the other two groups, but this difference was due to the higher 
proportion of deceased patients in the transfusion group. There was no statistically significant difference 
in participation by gender (figure 4). Database participation varied with age, with older people more likely 
to participate. This difference was statistically significant and held true even when deceased patients were 
excluded from the analysis (figure 4).
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Figure 4. Percentage of eligible people participating in the database by age group at the end of 
2008, gender and source of infection
Description of database population
RNA results
RNA tests are used to test for circulating virus. Positive results indicate current infection. In general, 
ELISA/EIA tests are used as screening tests for HCV antibodies, and line-immunoassay tests (e.g. RIBA/
INNO-LIA) are used to confirm positive antibody results. The combination of a positive HCV antibody 
result and a negative RNA result indicates past infection.
As the vast majority of participants were diagnosed some years after infection, ever testing RNA positive 
was found to be an excellent indicator of chronic long-term infection. Most of those who ever tested RNA 
positive and subsequently cleared the virus have done so relatively recently (almost all as a result of anti-
viral treatment) as the median duration of RNA positivity for those who ever tested positive (29 years) 
was found to be similar to the median time between infection and end of latest follow-up (30 years). 
Throughout this report, we treat participants who ever tested RNA positive as having been chronically 
infected with HCV and these participants are the primary focus when looking at clinical outcomes and 
disease progression to date.
We have no way of knowing the timing of viral clearance for participants who cleared the virus 
spontaneously prior to HCV testing (and thus had no positive RNA results). However, studies have found 
that spontaneous viral clearance usually occurs within a year of infection, so we assumed that these 
participants experienced acute infection only and were never chronically infected.19,20
In order to facilitate the comparison of participants who developed chronic infection and those who 
cleared the virus spontaneously after acute infection with HCV and never developed chronic infection, 
most data are presented separately for participants who ever tested RNA positive and those who had 
RNA tests done but had no positive RNA results. The participants who had no RNA results in their charts 
were omitted from most of the results presented by RNA status as they could not be classified as either 
“ever” or “never” testing RNA positive.
Overall, 62% (n=806) of database participants had at least one positive RNA result in their charts (figure 
5) and a further 15% (n=193) had positive confirmatory tests for HCV antibodies but no positive RNA 
results. The remaining 23% (n=304) tested either ELISA/EIA positive or weak positive, or RIBA/INNO-LIA 
indeterminate, and had no other positive HCV results. People with positive or weak positive ELISA/EIA 
tests or indeterminate RIBA/INNO-LIA tests were included in the database as many patients were tested 
many years after suspected infection, had documented exposure to HCV and may have cleared the virus 
and since sero-reverted. HCV antibody levels have been demonstrated to drop below detection limits in 
some patients.21,22,23
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Twenty three percent (n=37) of participants infected through clotting factors had no RNA test results 
in their charts (figure 5). All were deceased and most had died in the early to mid 1990s. RNA tests 
were only commonly used from 1994 onwards in Ireland. These participants were found to be similar to 
participants known to be chronically infected in terms of liver-related outcomes and it is likely that a large 
proportion would have been RNA positive if they had been tested prior to their death.  
Once participants with no RNA results were excluded, the overall spontaneous viral clearance rate, as 
determined by testing RNA negative at the time of first diagnosis, was 36%. This varied by gender and 
source of infection. Females (n=411, 41%) were significantly more likely to have cleared the virus by the 
time of their diagnosis than males (n=36, 14%). This gender imbalance remained but was significantly 
lessened when anti-D participants were excluded (23% for females compared to 14% for males). 
Some participants did not have positive confirmatory results for HCV. A small proportion of these may 
have had false positive ELISA/EIA results, making the viral clearance rate appear higher than it actually 
was. When only participants with positive confirmatory results for HCV were analysed, 19% had cleared 
the virus spontaneously by the time they were diagnosed. Therefore the true viral clearance rate is likely 
to be between 19 and 36%.
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Figure 5. Hepatitis C RNA results for all participants and by source of infection (n=1303)
End of latest follow-up
Data up to the end of 2008, where available, were collected for this round of data collection. However, 
latest follow-up for each participant is effectively the last time they visited their hepatology unit or their 
date of death as this is the last date when information was recorded in their medical charts. 
Of the living patients who became chronically infected, last hospital follow-up was in 2008 for 82%, 2007 
for 8%, 2006 for 4% and 2005 or earlier for 6%. Participants who did not become chronically infected 
were less likely to have been followed up recently: 49% last attended in 2008, 15% in 2007, 7% in 2006 
and 30% in 2005 or earlier. Some database participants are likely to have moved abroad and may be 
lost to follow-up and some of the participants who never became chronically infected may have been 
discharged to the care of their GPs.
Age, gender, source of infection, duration of infection and genotype
Participants infected through contaminated anti-D
The anti-D group is entirely composed of females who were infected during their child-bearing years 
(median age: 28 years) (figure 6, table 13). As a group, they would be expected to have been relatively 
healthy when infected. 
Infection due to contaminated anti-D has been largely traced to batches of anti-D from two infected 
donors.24 Batches from the first donor were contaminated with genotype 1 HCV and were distributed 
between 1977 and 1979. Eighty four percent (n=676) of anti-D participants were infected during this 
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period. Batches from the second donor were infected with genotype 3 HCV. These were administered 
between 1991 and 1994 and accounted for ten percent (n=78) of participating anti-D participants. The 
genotypes for one participant infected between 1977 and 1979 and for five participants infected between 
1991 and 1994 did not match the outbreak genotypes. The estimated year of infection for the remaining 
fifty participants was outside of these outbreak periods and sixty six percent (n=33) did not have positive 
confirmatory results for HCV. The source of their infection is unclear.
By latest follow-up, the median age of anti-D participants who became chronically infected was 57 years 
and the median duration of RNA positivity was 31 years (table 13). Eighty three percent had been RNA 
positive for 25 years or longer.
Participants infected through contaminated blood transfusions or treatment for renal disease
This group was the most heterogeneous in terms of age and gender (figure 6, table 13). They had the 
highest median age at infection (33 years for the group as a whole and 32 years for chronically infected 
participants), but this ranged from 0 to 77 years. Fifty seven percent of chronically infected participants 
were female and forty three percent were male, making this the only group with sizeable proportions of 
each gender. Using the assumptions outlined in chapter 3, most of the blood transfusion/renal participants 
were infected in the late 1970s and 1980s. They had the shortest duration of RNA positivity at latest 
follow-up, with 34% positive for 25 years or longer. At latest follow-up, the median age of transfusion/
renal participants who became chronically infected was 60 years and the median duration of RNA 
positivity was 21 years (table 13).
Participants infected through contaminated blood clotting factors
Participants infected through clotting factors were predominantly male (94%) and 42% were co-infected 
with HIV (figure 6). Using the assumptions outlined in chapter 3, most were infected as children in the 
mid-1970s to early 1980s. The median age at infection was 13 years for the group as a whole and 14 years 
for those who were chronically infected (table 13). By latest follow-up, the median age for clotting factor 
participants who became chronically infected was 45 years and the median duration of RNA positivity was 
29 years (table 13). Seventy one percent were RNA positive for 25 years or longer.
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Figure 6. Number of chronically infected participants by gender and source of infection (n=806) 
Note: The ‘All’ category includes 3 participants with “other” sources of infection.
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Table 13. Summary of age at infection, age at end of latest follow-up, years since infection and 
duration of RNA positivity by source of infection for chronically infected participants
Source of infection  Age at infection
Age at end of 
follow up
Duration of 
infection (years 
since infection)
Duration RNA 
positivity 
Anti-D Median 28 57 31 31
 Minimum 17 31 9 2
 Maximum 44 75 42 42
Anti-D 1977-1979 Median 28 58 31 31
 Minimum 17 33 17 15
 Maximum 44 75 32 32
Anti-D 1991-1994 Median 30 45 15 6
 Minimum 19 31 10 2
 Maximum 39 55 17 16
Transfusion/renal Median 32 60 23 21
 Minimum 0 16 1 1
 Maximum 77 91 47 46
Clotting factors Median 14 44.5 31 28.5
 Minimum 0 18 14 12
 Maximum 53 81 48 48
All Median 28 57 30 29
 Minimum 0 16 1 1
 Maximum 77 91 48 48
Genotype
The HCV genotype was available for nearly all of the database participants who became chronically 
infected (n=767, 95%). Genotype 1 predominated: 76% (n=584) were infected with genotype 1, 19% 
(n=142) were infected with genotype 3, 5% (n=37) were infected with genotype 2 and four participants 
were infected with genotypes 4 or 5 (figure 7).
Genotype 1 was significantly more common in anti-D participants compared to transfusion/renal or 
clotting factor participants. This is due to the large group of females infected with genotype 1 HCV 
through batches of anti-D administered between 1977 and 1979. Ninety percent of the anti-D participants 
who have been genotyped had genotype 1 HCV compared to 58% of blood transfusion/renal participants 
and 63% of blood clotting factor participants (figure 7).
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Figure 7. Distribution of hepatitis C genotypes by source of infection (n=763, genotypes 4 & 5 
omitted, n=4)
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Alcohol consumption
The recommended upper limits for alcohol consumption for the general population in Ireland are 21 units 
per week for males and 14 units per week for females.25 Participants consuming between these limits 
and 40 units per week were classified as having moderately high alcohol intake and those consuming 
over 40 units were classified as having high alcohol intake. Some data on units of alcohol were available 
for 90% of all participants, and 92% of those who became chronically infected. However, it is unusual for 
alcohol consumption to have been recorded at every visit, and in many cases it was last recorded many 
years ago. Alcoholic liver disease or alcohol abuse was also mentioned in the charts of some participants. 
This additional information was combined with alcohol intake data when looking at the effects of alcohol 
on disease progression and these participants were considered to have had high alcohol intake at some 
stage. Alcohol intake in excess of the recommended limits was recorded in the medical charts of 15% of 
chronically infected participants for whom data were available (table 14).
Table 14. Highest recorded alcohol intake for all database participants and by RNA status (where data 
available, n=1168, 90%)*
Alcohol consumption All Chronically infected
Never chronically 
infected
 Number % Number % Number %
Non drinker 292 25.0 181 24.4 105 25.9
Within recommended limits 729 62.4 453 61.0 268 66.0
Moderately high 64 5.5 45 6.1 18 4.4
High 83 7.1 64 8.6 15 3.7
Total 1168 100.0 743 100.0 406 100.0
* no alcohol intake data for 135 database participants, RNA status not known for 19 participants with alcohol intake data. Data 
for these participants shown under the “All” category, but not under the “Chronically infected” and “Never chronically infected” 
categories.
Differences in alcohol consumption by gender and source of infection
Males and females differed in their reported exposure to alcohol with 32% (n=59) of chronically infected 
males exceeding the recommended limits for alcohol intake compared to 9% (n=50) of females (figure 
8). Alcohol consumption also differed by source of infection with participants infected through anti-D 
significantly less likely to consume alcohol in excess of recommendations compared to those infected 
through other means (figure 9). However, this is likely to be largely attributable to the differences in 
gender distribution by source of infection. 
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Figure 8. Distribution of highest reported alcohol consumption by gender for participants who 
became chronically infected (where data available, n=743, 92%)
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Figure 9. Distribution of highest reported alcohol consumption by source of infection for participants 
who became chronically infected (where data available, n=740, 92%)
Changes in alcohol consumption between first visit to the hepatogy unit and subsequent visits for 
chronically infected participants 
Alcohol data were available at first and at least one subsequent visit to the hepatology units for 359 
(45%) chronically infected participants. These data were more likely to be available for participants who 
had high (92%) or moderately high (71%) alcohol consumption than for those whose consumption was 
within recommended limits (47%) or who were non drinkers (32%). Where data were available, 22% (n=77) 
initially consumed alcohol in excess of recommended limits. Latest data for these participants show a 
significant reduction with 7% (n=26) having moderately high or high alcohol intake (table 15, figure 10).
Table 15. Changes in alcohol consumption for chronically infected participants (where data available 
at first and subsequent visits to the hepatology unit, n=359, 45%)
Changes in alcohol consumption Number %
No change: moderately high or high 15 4.2
Decrease: high or moderately high to within limits/non drinker 62 17.3
Increase: within limits/non drinker to moderately high or high 11 3.1
No change: within limits/non drinker 271 75.5
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Figure 10. Changes in alcohol consumption for chronically infected participants (where data available 
at first and subsequent visits to the hepatology unit, n=359, 45%)
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Outcomes
Medical conditions 
Medical conditions recorded in participants’ medical charts were entered into the database.  However, 
these conditions may not have always been diagnosed according to standardised criteria and may not 
be related to HCV infection. Some medical conditions may also be underestimated if patients are treated 
privately and the condition is not discussed with the consultant hepatologist. However, if the condition 
was serious or known to be associated with HCV infection it is more likely to have been reported and 
recorded. 
Without a comparison group, it is not possible to determine if the prevalence of these conditions and 
procedures differed from the general population. However, if the condition was strongly associated with 
HCV infection, we would expect to see a significant difference in the prevalence of the condition between 
participants who became chronically infected and those who cleared the virus after acute infection. We 
excluded medical conditions that were known to pre-date HCV infection, but the year the condition was 
diagnosed was not always known.  
Table 16 shows the most common medical conditions recorded by RNA status and indicates conditions 
where there is statistically significant difference (Chi-square test p < 0.05) in the prevalence of the 
condition between participants who were ever chronically infected and those who were not. Differences 
should be interpreted with caution as follow-up was better for chronically infected participants and this 
may have led to a bias in the reporting and recording of medical conditions.
Depression was recorded in the medical charts of 359 participants. The prevalence was significantly higher 
for chronically infected participants (n=264, 33%) compared to those who did not become chronically 
infected (n=95, 21%). Females were more likely to report depression than males after accounting for the 
effects of RNA status. Participants who had received anti-viral treatment were also more likely to have 
depression recorded in their medical charts. Long-term medications for depression, sleep disorders or 
anxiety were noted in the charts of 60% (n=160) of chronically infected participants with depression. 
Osteoporosis was significantly more likely to be recorded for females, participants who were older at most 
recent follow-up and those who became chronically infected
Participants who were male, who were older at infection or older at latest follow-up, and those who 
became chronically infected, were significantly more likely to have diabetes. 
Twenty percent of chronically infected females had hysterectomies compared to 16% of those who 
never became chronically infected. The difference in hysterectomy prevalence by RNA status was not 
statistically significant. A study looking at hysterectomies in a population of 17,735 Irish women aged 
between 50 and 65 years who attended breast screening services was carried out in 2000. The prevalence 
of hysterectomies in this population was 22% and the peak age at the time of the operation in this 
population was 45-49 years.26 The prevalence in female database participants in the same age group was 
20% and did not differ according to HCV RNA status. The median age at operation was also similar (43 
years for chronically infected participants and 44 years for those who did not become chronically infected).
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Table 16. Medical conditions recorded in charts of participants – most common conditions and other 
conditions of interest* excluding conditions known to pre-date hepatitis infection
Disease or condition Chronically infected
Never chronically 
infected
Statistically 
significant 
difference
Statistically 
significant 
difference in 
females
Statistically 
significant 
difference in 
males
 Number % Number %    
Malaise, fatigue and lethargy 261 32.4 132 29.5 No Yes No
Depression 265 32.9 94 21.0 Yes Yes No
Arthralgia and joint pain 195 24.2 113 25.3 No No No
Hypertension 168 20.8 69 15.4 Yes No No
Hysterectomy † 119 20.1 67 16.3  No  
Fibromyalgia or myalgia 108 13.4 43 9.6 Yes Yes No
Disorders of the thyroid gland 90 11.2 36 8.1 No Yes No
Anaemia 64 7.9 28 6.3 No No No
Cholecystectomy 83 10.3 36 8.1 No No No
Osteoarthritis 84 10.4 34 7.6 No Yes No
Osteopaenia & other disorders of 
bone density/structure
73 9.1 36 8.1 No No No
Chronic lower respiratory 
diseases
75 9.3 28 6.3 No Yes No
Dermatitis or eczema 69 8.6 20 4.5 Yes Yes Yes
Disorders of lipoprotein 
metabolism and other lipidaemias
41 5.1 43 9.6 Yes ‡ Yes ‡ No
Diabetes 62 7.7 15 3.4 Yes Yes No
Dry/itchy/gritty eyes or 
conjunctivitis
57 7.1 23 5.1 No No No
Helicobacter pylori 51 6.3 23 5.1 No No No
Irritable bowel syndrome 39 4.8 27 6.0 No No No
Osteoporosis 55 6.8 10 2.2 Yes Yes No
Operations on appendix 45 5.6 18 4.0 No No No
Hiatus hernia 37 4.6 23 5.1 No No No
Excessive, frequent and irregular 
menstruation †
34 5.8 25 6.1  No  
Gastro-oesophageal reflux 
disease
46 5.7 11 2.5 Yes Yes No
Alcohol abuse or excess 45 5.6 7 1.6 Yes Yes No
Gastric,  duodenal or other 
peptic ulcer
36 4.5 20 4.5 No No No
Anxiety disorders 42 5.2 13 2.9 No Yes No
Sicca/Sjorgen syndrome or 
polymyalgia rheumatica
20 2.5 6 1.3 No No No
Operations on thyroid, 
parathyroid, other endocrine 
glands
19 2.4 6 1.3 No No No
Diseases of the gallbladder 20 2.5 2 0.4 Yes Yes No
Thrombocytopenia and other 
Purpura
18 2.2 3 0.7 Yes Yes No
Sarcoidosis 7 0.9 3 0.7 No No No
Cryoglobulinaemia 6 0.7 1 0.2 No No No
Neuropathies 5 0.6 1 0.2 No No No
Non-Hodgkin’s lymphoma 5 0.6 0 0.0 No No No
Parkinson’s disease 3 0.4 2 0.4 No No No
Myeloid leukaemia 3 0.4 1 0.2 No No Yes
Lupus erythematosus 3 0.4 0 0.0 No No No
* All conditions where n>45 are included. Data for some other conditions, mentioned in literature, or raised by patient groups, are also 
included (darker blue). Conditions known to pre-date hepatitis C infection were excluded from this table.
† Percentage calculated using female denominator figures.
‡ Participants who were never chronically infected were more likely to have this condition than those who were chronically infected. For 
all other conditions where statistically significant differences are indicated, prevalence was higher in chronically infected participants.
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Liver function tests – alanine aminotransferase (ALT)
Ninety four percent of database participants had at least one ALT result in their charts and 69% had two 
or more tests done. Levels were elevated on at least one test for 60% of chronically infected participants 
and 12% of those with no positive RNA results. Two of more abnormally high ALT results were recorded 
for 35% of chronically infected participants and 2% of participants who did not develop chronic infection. 
Nineteen percent of chronically infected participants had ALT levels 2.5 or more times the upper normal 
limit on at least one test compared to 1% of those who were not chronically infected.
In addition to chronic infection, the independent risk factors for ever having elevated ALT levels and for 
having ALT levels 2.5 or more times the upper normal limit on any test were: male gender, moderately 
high or high alcohol consumption and being infected for over 30 years. Table 17 shows the highest ALT 
results by source of infection for chronically infected database participants.
Table 17. Highest alanine aminotransferase results by source of infection for ever chronically infected 
participants 
Alanine aminotransferase results All Anti-D
Transfusion/ 
renal
Clotting factors
 Number % Number % Number % Number %
Normal 313 40.0 157 36.9 124 47.2 30 32.6
Elevated: <2.5 times upper normal limit 320 40.9 195 45.9 86 32.7 38 41.3
Elevated: > 2.5 times upper normal limit 150 19.2 73 17.2 53 20.2 24 26.1
Total 783 100 425 100 263 100 92 100
Signs of serious liver disease
One hundred and sixty seven (12.8%) participants had one or more signs of serious liver disease recorded 
in their charts at latest follow-up (table 18). Ninety three percent of these (n=155) tested RNA positive 
at some stage, 4% (n=7) had no RNA results in their charts and 3% (n=5) never tested RNA positive. The 
most common conditions or signs recorded were cirrhosis, varices, ascites and portal hypertension.
Table 18. Number and percentage of participants with signs of serious liver disease by RNA status
 
All Chronically infected
Never chronically 
infected
Serious signs of liver disease Number % Number % Number %
Cirrhosis 116 8.9 111 13.8 0 0.0
Hepatomegaly or splenomegaly or both 64 4.9 60 7.4 4 0.9
Varices 60 4.6 58 7.2 0 0.0
Portal hypertension 48 3.7 47 5.8 0 0.0
Ascites 47 3.6 43 5.3 3 0.7
HCC 25 1.9 23 2.9 0 0.0
Encephalopathy 22 1.7 20 2.5 1 0.2
Decompensated liver disease 11 0.8 10 1.2 0 0.0
Hepato Renal Syndrome 1 0.1 1 0.1 0 0.0
Hepatic Synthetic Dysfunction 1 0.1 1 0.1 0 0.0
Portal Gastropathy 1 0.1 1 0.1 0 0.0
Hepatopulmonary syndrome 1 0.1 1 0.1 0 0.0
One or more signs of liver disease 167 12.8 155 19.2 5 1.1
*7 participants with one or more signs of liver disease (including 5 with cirrhosis) had no RNA results in their charts.
Cirrhosis
By latest follow-up, 14% (n=111) of chronically infected participants had developed cirrhosis (table 18). 
Sixty nine were female (12% of RNA positive females) and forty two were male (20% of RNA positive 
males). Five deceased participants with no RNA results in their charts had also developed cirrhosis. For 
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RNA positive database participants, the median duration of RNA positivity at the estimated date of 
cirrhosis (see chapter 3) was 21 years and the median age at cirrhosis was 51 years.
The number of participants with cirrhosis has increased by 19 since the last round of data collection. Six 
were new database participants and two had previous comments relating to potential cirrhosis which were 
since clarified. The remaining eleven were newly diagnosed with cirrhosis since their previous visit to the 
hepatology unit. Four were estimated to have developed cirrhosis in 2008, six in 2007 and one in 2006.
Note: A diagnosis of cirrhosis was assigned if cirrhosis was mentioned in the patient’s medical chart 
(whether ever diagnosed by biopsy, ultrasound scan, CT scan etc) or on death certificate. Based on biopsy 
results alone, 78 of 644 chronically infected participants (12.1%) ever had a diagnosis of cirrhosis.
After RNA status, alcohol consumption was the biggest determinant of risk of cirrhosis in the database 
cohort. Where alcohol data were recorded, 26% of chronically infected participants with cirrhosis had 
consumed over 40 units of alcohol per week or had alcohol abuse or alcoholic liver disease recorded 
in their charts at some stage (table 19). Male gender and older age at latest follow-up were additional 
independent risk factors for cirrhosis. The prevalence of cirrhosis also varied by source of infection, with 
participants infected through transfusions/treatment for renal disease and those infected through clotting 
factors significantly more likely to have developed cirrhosis. However, this may be due to differences in 
the demographic and lifestyle characteristics of the different source groups (table 19).
Table 19. Summary of cirrhosis by source of infection for chronically infected participants
Source of infection
Number with 
cirrhosis
% with 
cirrhosis
% of those with 
cirrhosis with 
high alcohol 
consumption
Median age at 
cirrhosis in years 
(range)
Median duration 
RNA positivity at 
cirrhosis in years 
(range)
Anti-D 38 8.8 23.7 49 (37 - 69) 21 (7 - 31)
Transfusion or renal 58 21.6 25.0 55 (23 - 80) 19.5 (2 - 45)
Clotting factors 14 13.5 30.8 43 (31 - 57) 26 (13 - 36)
Hepatocellular carcinoma (HCC)/liver cancer
By latest follow-up, 23 (3%) chronically infected participants and two participants with no RNA results 
had developed HCC or liver cancer. This is an additional three participants compared to the first round of 
follow-up data collection. 
Eight were female (1.4% of RNA positive females) and fifteen were male (7% of RNA positive males). 
Twenty two (88%) of the participants with HCC were known to be deceased. The cause of death was 
directly liver-related for eighteen, not liver-related for two and the death certificate was missing for 
the remaining two participants. The median duration of infection at the estimated date of HCC was 25 
years and the median age at HCC was 63 years. The prevalence of HCC was significantly higher in the 
transfusion/renal and clotting factor groups compared to the participants infected through contaminated 
anti-D (table 20). Where alcohol intake was available, eight (38.1%) had high alcohol use.
Table 20. Summary of HCC by source of infection for chronically infected participants
Source of infection Number with HCC % with HCC
Median age at HCC in 
years (range)
Median duration RNA 
positivity at HCC in years 
(range)
Anti-D 3 0.7 65 (45 - 67) 28 (25 - 29)
Transfusion or renal 15 5.6 70 (43 - 81) 21 (5 - 39)
Clotting factors 5 4.8 54 (49 - 61) 27 (19 - 36)
Biopsy results
Most of the biopsies were carried out in the mid to late 1990s, with much smaller numbers being done 
in more recent years (figure 11). Forty six participants had a biopsy in 2007 and thirty four had a biopsy 
in 2008. Overall, the likelihood of having a biopsy varied by RNA status with 83% of chronically infected 
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participants having a biopsy compared to 25% of those with no positive RNA results. Participants infected 
through contaminated clotting factors were least likely to have had biopsies, with only 37% of those 
ever testing RNA positive having biopsy results in their charts compared to 96% of chronically infected 
anti-D participants and 80% of those infected through blood transfusions or treatment for renal disease. 
Disease progression may be more likely to be monitored using ultrasounds, CT scans and other tests for 
participants infected through clotting factors and the available biopsy results in these participants are not 
likely to be a good indicator of disease status or progression.
Of the 1,634 biopsies carried out, inflammation grade was available for 99% and fibrosis score for 91%. 
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Figure 11. Number of biopsies done by year of biopsy and RNA status of participant
Inflammation
Twenty five percent (n=161) of chronically infected participants had moderate or severe inflammation on 
last biopsy compared to 1% of participants who did not become chronically infected. Inflammation grade 
on biopsy varied by source of infection with 46% of chronically infected transfusion/renal participants 
having moderate or severe inflammation on one or more biopsies compared to 35% of anti-D participants 
and 24% of participants infected through clotting factors. 
Fibrosis
Fibrosis was scored using different scoring systems in different units. Overall 78% of biopsies were scored 
using a 0-6 scoring system, and a 0-4 system was used for the remaining 22%. Biopsy results scored from 
0 to 6 were converted to the 0 to 4 scores (see chapter 3 for details) for some analyses to allow all biopsy 
results to be analysed together. 
We considered high fibrosis scores to be scores of 4-6 on biopsies scored from 0-6 and scores of 3-4 on 
biopsies scored from 0-4. Nineteen percent (n=122) of chronically infected participants had a high fibrosis 
score on their most recent biopsy (where fibrosis score was recorded, n=644) compared to 4% (n=4) of 
those who never tested RNA positive (where fibrosis score was recorded, n=104). Fibrosis also varied by 
source of infection. Thirty three percent (n=65) of chronically infected blood transfusion/renal participants 
had a high fibrosis score on most recent biopsy compared to 24% (n=9) of clotting factor participants and 
12% (n=48) of anti-D participants (figure 12).  
For chronically infected participants who ever had a high fibrosis score on biopsy, the median age at first 
biopsy with a high score was 51 years (range: 22-76) and the median duration of infection was 19 years 
(range: 0 to 39 years).  
In those who were chronically infected, a high fibrosis score was associated with high alcohol 
consumption, older age at last biopsy, longer duration of infection, male gender and genotype 3 infection.
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Figure 12. Fibrosis score* on last biopsy for chronically infected participants by source of infection 
(n=644)
*All 0-6 scores standardised to 0-4 (see chapter 3 for description) to allow all biopsies to be analysed together. 
Note: results for clotting factor participants are not representative as data are only available for 37 and the last biopsy was several 
years ago for many patients.
Rate of fibrosis progression for untreated chronically infected participants 
Six hundred and seven chronically infected participants (75%) had biopsy results with fibrosis scores before 
or without undergoing anti-viral treatment or transplants. The median duration of infection at last scored 
biopsy before treatment or transplant for these participants was 20 years. Nineteen percent had high 
fibrosis scores. In order to look at the rate of fibrosis progression for these patients, we assumed that all 
had fibrosis scores of 0 when infected. The overall estimated fibrosis rate was 0.064 units of fibrosis per 
year of infection (range: 0-1.022), meaning that the expected time from infection to cirrhosis would be 
62.5 years in this cohort overall. Progression rates were lower in females who had never had high alcohol 
intake and who had been infected when aged less than 40 years (n=429, 0.05 units per year, 80 years from 
infection to cirrhosis) and higher in participants with high alcohol consumption (n=35, 0.15 units per year, 
27 years from infection to cirrhosis).
Changes in biopsy results post-treatment
One hundred and eight chronically infected participants had pre- and post-treatment biopsy results. The 
changes in fibrosis scores (all standardised to 0 to 4 system) by anti-viral treatment response are shown in 
figure 13. Fibrosis scores improved for 56% (n=27) of those who achieved sustained virological response 
(SVR) on treatment compared to 30% (n=18) of those who did not. 
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Figure 13. Changes in fibrosis scores (0-4) after treatment by SVR status for participants who had pre- 
and post-treatment biopsy results (n=108)
*All 0-6 scores standardised to 0-4 (see chapter 3 for description) to allow all biopsies to be analysed together. 
Note: Numbers in some categories are very low and percentages should be interpreted with caution.
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Deceased participants
One hundred and eighty eight participants had died by latest follow-up. This represents fifteen additional 
deceased participants compared to the first round of follow-up data collection. Five died in 2007, eight 
died in 2008 and the remaining two participants died several years ago but were not previously included 
in the database. All cause mortality rates varied significantly by RNA status: 16% of chronically infected 
participants were deceased by latest follow-up compared to 4% of participants who never became 
chronically infected (figure 14). Mortality rates were also higher in males or participants infected through 
blood transfusions or clotting factors, those who had high alcohol intake and participants who were older 
when infected.
Where death certificates were available (n=177), death was directly caused by liver disease for 48 
participants. The underlying cause of death was coded to HCV infection for twenty, liver cell carcinoma 
for sixteen, hepatic failure for five, cirrhosis of the liver for three and other liver related conditions for 
four. HCV infection was one of the causes of death listed on the first part of the death certificate for thirty 
seven of the participants who died from liver-related causes. The first part of the death certificate details 
the chain of diseases or conditions leading directly to death.
Liver-related mortality rates were higher in participants who were chronically infected with HCV or had no 
RNA results compared to those who had no positive RNA results in their charts (figure 15). Thirty eight of 
those who died from liver-related causes were chronically infected, eight had no RNA results in their charts 
and the remaining two had RNA results in their charts, but had never tested RNA positive. High alcohol 
intake was a highly significant predictor of liver-related mortality. Information on alcohol consumption was 
available for 81% of those whose death was caused by liver disease. Forty nine percent had indicators of 
high levels of alcohol consumption in their medical charts. Liver-related mortality rates were also higher 
in males or participants infected through blood transfusions or clotting factors and participants who were 
older when infected.
The most common non-liver related causes of death for chronically infected participants were cancer, heart 
disease, renal disease and HIV/immunodeficiency (discussed in more detail in the section ‘Participants 
infected through contaminated blood clotting factors’). 
Figure 14. Comparison of survival for participants who ever tested hepatitis C RNA positive and those 
with RNA results in their chart but with no positive results
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Figure 15. Comparison of survival from liver-related death for participants who ever tested hepatitis C 
RNA positive and those with RNA results in their chart but with no positive results
Table 21. Number and percentage of participants who died directly from liver-related disease, by 
source of infection
Source of infection
Died directly from liver-
related disease *
% of participants who died 
directly from liver-related 
disease
% of chronically infected 
participants who died directly 
from liver-related disease
Anti-D 8 1 1.4
Transfusion/renal 21 6.4 7.5
Clotting factors 18 11.5 10.7
Total* 48 3.7 4.8
*One participant who died directly from liver-related disease was missing information relating to source of infection
Changes in the prevalence of the main liver-related outcomes since baseline 
data were collected
HCV disease progresses particularly after two to four decades of infection.6 The median time since 
infection for the database population is now 30 years and the median duration of RNA positivity for those 
who became chronically infected is 29 years. This is our third round of data collection and we can clearly 
see increases in the prevalence of liver-related health outcomes since baseline data were collected  
(figure 16).
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Figure 16. Changes in the prevalence of liver-related outcomes for chronically infected participants 
since baseline data were collected  
Note: Percentages at baseline may differ slightly from baseline report due to slight changes in the way results are coded or analysed 
or where data are extracted from. The denominators may also have changed slightly due to the identification of several ineligible 
patients or duplicates.
Summary of disease progression and factors associated with disease severity
As there were several outcome measures that could be used to indicate HCV disease severity, a variable 
was created to summarise disease progression. 
A participant was considered to have ‘severe liver disease’ if they had:
•Diedfromliver-relateddiseaseor
•Everhadoneormoreofthefollowingsignsofliverdisease:cirrhosis,primarylivercancer,ascites,
varices, decompensated liver disease, portal hypertension, encephalopathy, hepatomegaly or 
splenomegaly or
•Everhadafibrosisscoreof3or4onabiopsyscoredfrom0to4orascorebetween4and6ona
biopsy scored from 0 to 6 (note: this is “worst” biopsy result, not necessarily most recent one; some 
patients may have improved on treatment)
A participant was considered to have ‘moderate liver disease’ if they had none of the above and had 
either:
•Afibrosisscoreof2onabiopsyscoredfrom0to4orascoreof3onabiopsyscoredfrom0to6or
•Moderateorsevereinflammationonanybiopsy
All other participants were classified as having ‘mild or no liver disease’. 
Using these criteria, 27% (n=217) of chronically infected participants, 22% (n=11) of participants with no 
RNA results and 2% (n=7) of those who never tested RNA positive were classified as having severe liver 
disease by latest follow-up. A further 20% of chronically infected participants and 1% of those who never 
became chronically infected were classified as having moderate liver disease. By latest follow-up, 53% 
of chronically infected participants and 97% of participants who never became chronically infected were 
classified as having mild or no liver disease.
 
Tables 22 and 23 show the effects of some key host and virus characteristics on the odds of having severe 
liver disease. Only participants who tested RNA positive at some stage (ever chronically infected) were 
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included in these analyses as 92% of the 235 participants with severe disease had tested RNA positive and 
this approach allowed the effects of genotype to be assessed. 
The determinants of having severe liver disease in the database cohort were high alcohol intake, older age 
at end of latest follow-up, male gender, longer duration of RNA positivity and HCV genotype 3 (table 22). 
Table 23 shows the same model with source of infection substituted for gender. These factors cannot be 
assessed together using a logistic regression model as gender is too closely linked to source of infection 
in the database population. This model indicates that participants infected through blood transfusions/
treatment for renal disease and those infected through clotting factors were more likely to have severe 
liver disease by latest follow-up compared to those infected through anti-D. All associations between 
these characteristics and severe liver disease were statistically significant and the influence of each of 
these factors on disease severity was independent of the effects of all of the other factors in the table. 
The most important factor in disease progression was alcohol intake. Participants who had high alcohol 
intake had almost five times higher odds of having severe disease than those without. However, the 
number of chronically infected database participants with high alcohol intake was low (n=64) and due to 
its sensitivity, alcohol consumption data may be inaccurately reported. Figure 17 shows the prevalence of 
severe liver disease by duration of RNA positivity and alcohol intake.
Participants who were RNA positive for more than twenty years had approximately two fold higher odds of 
having severe liver disease compared to those infected for less than twenty years. The odds of having severe 
liver disease were almost three times higher for males compared to females. Participants who were aged 
50 years or older at latest follow-up were more likely to have severe liver disease than younger participants. 
Table 22. Factors associated with severe liver disease in chronically infected participants - logistic 
regression model (n=710) 
Factors associated with having severe liver disease Odds Ratio P-value 95% Confidence interval
Alcohol consumption    
Non drinker/within recommended limits/moderately high 1 Reference Reference
High (>40 units per week or alcohol abuse in chart) 4.96 <0.001 2.72 - 9.06
Age at end of latest follow-up    
<50 years 1 Reference Reference
50 to 64 years 2.29 0.002 1.37 - 3.84
65+ years 3.29 <0.001 1.87 - 5.80
Gender    
Female 1 Reference Reference
Male 2.85 <0.001 1.83 - 4.44
Genotype    
Genotype 1 1 Reference Reference
Genotype 2 0.92 0.849 0.37 - 2.24
Genotype 3 2.00 0.008 1.20 - 3.34
Duration of RNA positivity    
<20 years 1 Reference Reference
20+ years 1.88 0.016 1.12 - 3.14
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Table 23. Factors associated with severe liver disease in chronically infected participants - logistic 
regression model (n=708) 
Factors associated with having severe liver disease Odds Ratio P-value
95% Confidence 
interval
Alcohol consumption    
Non drinker/within recommended limits/moderately high 1 Reference Reference
High (>40 units per week or alcohol abuse in chart) 4.65 <0.001 2.54 - 8.53
Age at end of latest follow-up    
<50 years 1 Reference Reference
50 to 64 years 1.92 0.013 1.15 - 3.20
65+ years 2.26 0.005 1.28 - 4.00
Source of infection    
Anti-D 1 Reference Reference
Transfusion/renal 3.08 <0.001 1.97 - 4.81
Clotting factors 2.25 0.015 1.17 - 4.34
Genotype    
Genotype 1 1 Reference Reference
Genotype 2 0.64 0.330 0.26 - 1.57
Genotype 3 1.70 0.042 1.02 - 2.84
Duration of RNA positivity    
<20 years 1 Reference Reference
20+ years 2.17 0.003 1.30 - 3.64
Explanatory note: The odds ratios shown are a measure of the odds of severe liver disease in one group 
(e.g. males) divided by the odds of severe disease in another group (the reference group e.g. females). 
An odds ratio of 1 indicates that severe liver disease is equally likely in both males and females and an 
odds ratio of more than 1 for males indicates that severe disease is more likely in males. P-values of <0.05 
were taken to indicate a statistically significant difference between the distribution of severe disease in the 
category of the factor being assessed and the reference category of that factor.
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Figure 17. Percentage of chronically infected participants with severe liver disease by source of 
infection, duration of RNA positivity and alcohol consumption 
Note: Numbers in some categories are very low and percentages should be interpreted with caution
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Anti-viral treatment for hepatitis C
Almost 41% (n=329) of chronically infected participants had one or more courses of anti-viral treatment by 
latest follow-up. Participants stopping treatment early are included when calculating sustained virological 
response (SVR). The SVR rate has improved in recent years with the advent of combination therapy with 
pegylated interferon (Peg-IFN) and ribavirin (RBN) (figure 18). Tolerance of anti-viral treatment remains an 
issue, with 24% of all treatment courses stopped early due to side-effects. This was slightly higher for 
monotherapy with interferon (IFN) or Peg-IFN (28%) than for combination therapy (22%).
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Figure 18.Treatment courses by type of treatment and percentage sustained virological response, 
1992-2008 
Note: Outcome awaited for 12 participants – not included when calculating SVR
Younger participants, those infected through blood transfusions or clotting factors, those with higher 
fibrosis scores and participants with genotype 2 or 3 infections were more likely to have been treated 
(table 24). However, of the 48 participants who commenced treatment between 2006 and 2008, 35 (73%) 
were genotype 1. This was their first course of treatment for 34, second course for 12 and third course for 
2 participants. A high fibrosis score was recorded for 11 (23%) of these recently treated participants.
Table 24. Number and percentage of chronically infected participants treated, and percentage SVR, 
by fibrosis scores, hepatitis C genotype, source of infection and age at latest follow-up
Characteristic Number treated % treated
% SVR on first 
treatment
% SVR on last 
treatment
High fibrosis scores on 
any biopsy
Yes 95 61.7 19.2 31.5
 No 196 38.1 42.9 54.8
Hepatitis C genotype 1 194 33.2 22.5 31.7
 2 25 67.6 41.7 66.7
 3 100 70.4 56.6 72.2
Source of infection Anti-D 142 33.0 34.1 45.1
 Transfusion/renal 135 50.2 38.1 48.9
 Clotting factors 52 50.0 33.3 51.0
Age at latest follow up <60 years 236 48.0 41.2 54.2
 60+ years 93 29.6 21.7 31.5
All participants  329 40.8 35.6 47.6
Note: Genotype not available for 9 participants who were treated. Participants with genotypes 4/5 omitted from analysis of 
treatment data. Fibrosis scores not available for 38 of the participants who were treated. Treatment outcome awaited for 12 
participants – these participants were not included when calculating SVR. 
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Treatment response  
Treatmentresponsefortreatmentnaïveparticipantsbygenotypeandtypeanddurationoftreatmentare
shown in figure 19. Seventy seven percent (n=10) of genotype 2 or 3 participants on combination therapy 
for 48 weeks or more achieved an SVR compared to 47% (n=23) of genotype 1 participants on the same 
treatment. 
Treatment response rates on the most recent treatment with combination therapy by genotype and 
duration of treatment are shown in figure 20.
The factors associated with SVR on treatment were: treatment with combination therapy rather than 
monotherapy, having HCV genotypes 2 or 3 rather than genotype 1, longer duration of treatment, 
younger age at treatment, female gender and lower fibrosis scores on biopsy. Participants infected 
through clotting factors were also less likely to achieve SVR than those infected through anti-D or blood 
transfusions after taking account of treatment type, genotype, duration of treatment, age at treatment 
and fibrosis score.  This may be partly explained by factors such as male gender, higher alcohol intake and 
high prevalence of HIV co-infection in the clotting factor group.
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Figure 19. Percentage sustained virological response for treatment of naïve participants by genotype 
and duration of therapy for monotherapy with IFN (n=141) or Peg-IFN (n=1), and combined therapy 
with IFN and RBN (n=80) or Peg-IFN and RBN (n=88)
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Figure 20. Percentage sustained virological response on last treatment using combined therapy with 
IFN and RBN (n=92) or Peg-IFN and RBN (n=12) by genotype and duration of treatment 
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Treatment response: previously treated participants
Eighty seven participants had at least two courses of treatment by end of latest follow-up. Three were 
still on treatment when follow-up data were collected. Of the 84 remaining participants, the second 
treatment was with monotherapy for 14 (most of these were in the 1990s) and with combination therapy 
for 70. The numbers involved were small but there was some success when participants were re-treated 
using combination therapy, with 31% of those with genotype 1 and 67% of those with genotypes 2 or 
3 achieving SVR. Half (50%) of those achieving SVR on re-treatment with combination therapy had had 
a partial response to the previous course of treatment (initial response with breakthrough while still on 
treatment, or early relapse within six months of completion of treatment). In comparison, only 15% of 
those who did not achieve SVR on re-treatment had shown a partial response to previous treatment. This 
difference was statistically significant. 
 
Liver transplants 
Eighteen database participants had received twenty liver transplants by the end of 2008. Eleven received 
transplants in 2005 or earlier, three were transplanted in 2006, one in 2007 and three in 2008. The 
median age at transplant was 52.5 years (range: 29-66 years) and the median duration of HCV infection 
at transplant was 28.5 years (range: 1-41 years). All transplant recipients were RNA positive when 
transplanted and all of those tested post-transplant (n=14) remained RNA positive. 
Histological staging was available for fourteen patients prior to their transplant and all had cirrhosis at this 
stage. Results were available for nine patients post-transplant. Eight patients had biopsy results within four 
years of transplant. In this time, two had developed mild fibrosis, one had developed moderate fibrosis, 
three had developed advanced fibrosis or cirrhosis and two had developed HCC. The remaining patient 
had cirrhosis on a biopsy carried out more than 15 years after the transplant. 
Four of the liver transplant patients have since died, three from non-liver related causes and one from 
hepatocellular carcinoma. The median time between transplant and death for these patients was sixteen 
months.
Focus on the different patient groups
Database participants who became chronically infected with HCV through blood transfusions or treatment 
for renal disease had the highest prevalence of severe liver disease in spite of having the shortest 
median duration of RNA positivity at the end of latest follow-up. Thirty eight percent of transfusion/renal 
participants were classified as having severe liver disease, including 22% with cirrhosis, after a median 
duration of HCV RNA positivity by latest follow-up of 21 years. The prevalence of severe liver disease 
was also high in participants who were chronically infected through clotting factors, with 31% classified 
as having severe liver disease and 14% diagnosed with cirrhosis after a median duration of RNA positivity 
of 31 years. Chronically infected anti-D participants had better liver-related outcomes overall, with 19% 
classified as having developed severe liver disease, including 9% with cirrhosis, after a median duration of 
RNA positivity of 31 years.
There are several potential explanations for these differences in liver-related outcomes. Firstly, we would 
expect co-morbidities to be high in transfusion/renal participants in general, as many were infected with 
HCV as a result of treatment for serious medical conditions such as cancer. Transfusion/renal participants 
were also slightly older overall when infected with HCV, with a median age at infection of 32 years, 
compared to 28 years for anti-D participants and 14 years for participants infected through clotting 
factors. Gender may also be a factor as chronically infected female participants have a lower prevalence 
of serious liver-related outcomes than males in spite of having longer durations of RNA positivity. Alcohol 
intake also varies by gender and hence by source of infection, with 13% of chronically infected transfusion/
renal participants and 17% of chronically infected clotting factor participants consuming high levels of 
alcohol at some stage, compared to 4% of anti-D participants.
Participants infected through anti-D
In spite of having the longest median duration of RNA positivity, database participants infected through 
anti-D have the lowest prevalence of serious liver-related outcomes. This is likely to be attributable, in 
part, to the fact that this group was entirely composed of females who were infected during or after 
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pregnancy and who were likely to have been in relatively good health when infected with HCV. Reported 
alcohol consumption was also lower for female database participants. Their median age at infection was 
28 years, which makes them younger overall compared to the transfusion/renal group but significantly 
older than those infected through clotting factors. 
Anti-D participants infected between 1977 and 1979 have had the lowest uptake of antiviral treatment 
to date (n=101, 27%). This is probably due to the relatively low prevalence of progressive fibrosis in this 
group, combined with published information showing poorer treatment responses in genotype  
1 patients.11,27 The SVR was 30% in participants infected during the 1977-79 anti-D outbreak and 34% 
in other genotype 1 database participants. Treatment uptake in participants infected during the second 
anti-D outbreak (1991-1994) has been extremely high (n=33, 89%). The percentage achieving SVR has also 
been very high (90%), even in comparison with other genotype 3 database participants (64%). 
Demographic characteristics, liver-related outcomes and treatment data for participants infected during 
each anti-D outbreak period are shown in table 25.
Table 25. Summary of demographic characteristics, liver related outcomes and antiviral treatment 
data by anti-D outbreak
 
1977-1979 Anti-D 
outbreak
1991-1994 Anti-D 
outbreak
Characteristic Number % Number %
Hepatitis C genotype Genotype 1 Genotype 3
Chronically infected with hepatitis C 376 56.2 37 54.4
Median  age at infection (years) 28  30  
Median age at end of follow up (years) 58  45  
Median years since infection at end of follow up 31  15  
Mean duration RNA positivity (years) 31  6  
Alcohol intake     
 Alcohol data available - database study (highest 
reported alcohol used)
363  35  
<14 units per week 334 92.0 31 88.6
15 to 40 units per week 14 3.9 2 5.7
>40 units per week or alcohol abuse in chart 15 4.1 2 5.7
Serum alanine aminotransferase levels     
Data available 374  35  
Normal 124 33.2 25 71.4
 Slightly elevated (from upper normal limit to <2.5 times 
upper normal limit)
183 48.9 7 20.0
More highly elevated (>2.5 times upper normal limit) 67 17.9 3 8.6
Liver disease severity     
Mild 208 55.3 21 56.8
Moderate 91 24.2 13 35.1
Severe 77 20.5 3 8.1
Outcomes     
Signs of liver disease 45 12 3 8.1
Cirrhosis 35 9.3 2 5.4
HCC 3 0.8 0 0
High fibrosis score on biopsy 66 17.6 2 5.4
Deceased 30 8 0 0
Liver-related disease directly caused death 6 1.6 0 0
Hepatitis C treatment     
Treated 101 26.8 33 89.2
Treated and treatment response available 95 25.2 31 83.8
SVR on last treatment with monotherapy 23 17.4 16 100
SVR on last treatment with combined therapy 72 31.9 15 80
Overall SVR on last treatment  29.8  90.3
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Participants infected through blood transfusions or treatment for renal disease
Database participants infected through blood transfusions or treatment for renal disease had the highest 
rate of HCV chronicity at diagnosis. RNA results were missing for three, but where results were available, 
82% (n=269) were chronically infected and 18% (n=61) had cleared the HCV virus by this time.
The group of participants infected through blood transfusions or treatment for renal disease were the 
only patient cohort with a wide age distribution and significant proportions of both males and females, 
and both genotype 1 and 3 infections. These characteristics make this patient population a good one for 
examining the host and virus characteristics associated with liver disease severity. Logistic regression was 
used to model the factors that were independently and significantly associated with severe liver disease in 
this population (table 26).
High alcohol intake, older age at the end of latest follow-up, male gender, HCV genotype 3 and longer 
duration of infection were all found to be independently associated with severe liver disease in chronically 
infected blood transfusion/renal patients (table 26). It would be interesting to also examine the effects 
of factors such as BMI, steatohepatitis and insulin resistance on disease severity, but our data are not 
currently sufficient to allow for this. We hope to be able to improve on this in future rounds of data 
collection if the relevant data are recorded in the patient charts.
Table 26. Factors associated with severe liver disease in chronically infected participants infected 
through blood transfusions/treatment for renal disease - logistic regression model (n=228) 
Factors associated with having severe liver disease Odds Ratio P-value 95% Confidence interval
Alcohol consumption    
Non drinker/within recommended limits/moderately high 1 Reference Reference
High (>40 units per week or alcohol abuse in chart) 3.19 0.007 1.37 - 7.42
Age at end of latest follow up    
<50 years 1 Reference Reference
50+ years 3.05 0.002 1.49 - 6.26
Gender    
Female 1 Reference Reference
Male 2.60 0.003 1.39 - 4.86
Genotype    
Genotype 1 1 Reference Reference
Genotype 2 0.77 0.619 0.27 - 2.18
Genotype 3 2.59 0.004 1.36 - 4.93
Duration of RNA positivity    
<20 years 1 Reference Reference
20+ years 2.15 0.016 1.15 - 4.01
Participants infected through contaminated blood clotting factors 
Of the 161 database participants infected through blood clotting factors, 65% (n=104) were chronically 
infected with HCV at diagnosis and 23% (n=37) had no RNA results in their charts (figure 21). These 
patients had all died prior to RNA testing but had similar prevalence of serious liver-related outcomes 
to the chronically infected participants and it is likely that they were chronically infected with HCV when 
they died. The remaining 12% (n=20) had RNA results in their charts but had never tested positive. These 
participants showed no signs of serious liver-related disease by latest follow-up.
Thirty five percent (n=36) of the chronically infected participants and 84% (n=31) of those with no HCV 
RNA results were co-infected with HIV. It was difficult to ascertain the true effects of HIV co-infection on 
HCV disease progression as 66% (n=44) of the co-infected participants had died many years previously. 
However, 33% (n=22) of those who were HIV positive had signs of serious liver disease by latest follow-
up compared to 16% (n=12) of those who were HIV negative, even though they had a shorter median 
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duration of follow-up (25 years compared to 28 years) (figure 21). Where data were available (77%, n=99), 
high alcohol intake was also found to be associated with severe liver disease. Fifty six percent of HIV 
negative participants with high alcohol consumption were classified as having severe liver disease by latest 
follow-up compared to 16% of those who had not had high alcohol intake. The effects of alcohol on liver 
disease severity was much less pronounced and not statistically significant in HIV positive participants, with 
50% of those with high alcohol consumption classified as having severe disease compared to 42% of those 
without. However, because a significant proportion of these participants were deceased, they had been 
followed up for a shorter duration of time and were younger at the time of latest follow-up or death.
Death certificates were available for 41 of the 44 HIV positive participants who had died. The underlying 
cause of death was liver-related disease for nine and directly related to HIV infection for twelve. A further 
ten had causes of death relating to immunodeficiency, but the term HIV was not specifically mentioned on 
their death certificate. The underlying cause of death was classified as directly liver-related for 9 of the 22 
HIV negative participants who had died, not liver-related for 12 and the death certificate was missing for 
the remaining patient.
Forty one participants infected through blood clotting factors had received combination therapy for 
HCV by latest follow-up. The number treated was too low to reliably assess if treatment response varied 
with HIV status, but the response rates by type of treatment and genotype were not statistically worse in 
the co-infected participants. Of the twenty six genotype 1 participants treated, 33% of those who were 
co-infected with HIV achieved SVR compared to 41% of those who were not. Of the fifteen genotype 2 
or 3 participants treated, 86% of those who were co-infected with HIV achieved SVR compared to 75% 
of those who were not. These SVR rates were also comparable to those achieved by participants infected 
through other means (36% SVR for genotype 1 and 69% for genotype 3). 
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Clotting factor participants: Liver-related outcomes, HIV & alcohol
220 people identified as infected with hepatitis
C through blood clotting factors in Ireland
At the end of 2008: 73% participating in
hepatitis C database (n=161)
% with serious
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Figure 21. Summary of hepatitis C infection and disease progression in clotting factor participants by 
HIV status
Clinical management and health service usage
Long term medications other than anti-viral treatment 
The most common long-term medications used were drugs for acid-related disorders, drugs used to treat 
depression, anxiety or sleep disorders, cardiovascular drugs and anti-inflammatory and anti-rheumatic 
drugs (table 27). The proportion of chronically infected participants taking long-term medications to treat 
depression, anxiety or diabetes was significantly higher than that for participants who never became 
chronically infected.
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Table 27. Most common long-term medications recorded in medical charts
Medication type All participants
Chronically 
infected
Never chronically 
infected
 Number % Number % Number %
Drugs for acid related disorders 296 22.7 216 26.8 75 16.8
Psychoanaleptics 243 18.6 180 22.3 60 13.4
Psycholeptics 200 15.3 147 18.2 48 10.7
Analgesics 187 14.4 125 15.5 56 12.5
Beta blocking agents 184 14.1 136 16.9 47 10.5
Mineral supplements 180 13.8 133 16.5 47 10.5
Agents acting on the renin-angiotensin system 161 12.4 115 14.3 46 10.3
Diuretics 152 11.7 114 14.1 38 8.5
Serum lipid reducing agents 151 11.6 78 9.7 73 16.3
Antiinflammatory and antirheumatic products 139 10.7 88 10.9 51 11.4
Drugs for treatment of bone diseases 128 9.8 90 11.2 38 8.5
Thyroid therapy 114 8.7 80 9.9 33 7.4
Antithrombotic agents 111 8.5 75 9.3 36 8.1
Calcium channel blockers 95 7.3 74 9.2 21 4.7
Drugs for obstructive airway diseases 88 6.8 60 7.4 27 6
Antianemic preparations 79 6.1 56 6.9 18 4
Sex hormones and modulators of the genital system 79 6.1 49 6.1 28 6.3
Drugs used in diabetes 77 5.9 58 7.2 17 3.8
Corticosteroids for systemic use 62 4.8 55 6.8 5 1.1
Vitamins 58 4.5 49 6.1 8 1.8
Antiepileptics 51 3.9 35 4.3 15 3.4
Immunosuppressive agents 48 3.7 45 5.6 3 0.7
Antihemorrhagics 45 3.5 36 4.5 7 1.6
Antivirals for systemic use 43 3.3 31 3.8 1 0.2
Antihypertensives 41 3.1 30 3.7 11 2.5
Drugs for functional gastrointestinal disorders 40 3.1 29 3.6 9 2
Visits to the hepatology unit
Seventy seven percent of all living database participants had attended their hepatology unit in 2007 or 
2008 and a further 3% had been followed up through other services within the same hospital in this time 
period. The frequency of attendance at the hepatology units varied with RNA status. Eighty eight percent 
of participants who had ever been chronically infected attended their unit in 2007 or 2008 and a further 
two percent were followed up through other services in the hospital. Participants who had never become 
chronically infected were less likely to have attended recently, with 60% attending in 2007 or 2008 and 
an additional 3% attending other services in the hospital. For participants who had attended hepatology 
services on an out-patient basis since last follow-up, the median number of visits was two for those who 
were ever chronically infected and one for those who had never become chronically infected.
After accounting for RNA status, anti-D participants were more likely to have attended their hepatology 
unit in 2007 or 2008 than participants infected through clotting factors or blood transfusions/treatment 
for renal disease. However, there was no difference in the proportion of participants with some follow-up 
data from 2007 or 2008 by source of infection, indicating that the transfusion/renal and clotting factor 
participants were just more likely to be followed up through other hospital services in addition to, or 
instead of, their hepatology unit. There was no difference in follow-up by severity of liver disease after 
accounting for RNA status.
Twenty two percent of living participants who were ever chronically infected and 11% of those who were 
never chronically infected had visited hospital on an in-patient basis since last follow-up. The median 
number of in-patient visits was one for both. Sixty eight percent of admissions were not liver-related. Liver 
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biopsies were the main liver-related reason for hospital admission (21% of all admissions). Other liver-
related reasons for admission include initiation of HCV treatment (n=8) and liver transplant (n=3).
Specialist health services and procedures
Since last follow-up, 42% (n=286) of ever chronically infected living participants and 23% (n=99) of 
those who were never chronically infected attended one or more specialist hospital services other than 
hepatology. The most common services used by chronically infected participants were haematology (10%), 
psychiatry/psychology/counselling (6.9%), endocrinology (6.2%) and rheumatology (5.8%) (table 28). As 
expected, a high proportion of participants infected through clotting factor attended haematology and 
physiotherapy services and a very high proportion of participants infected as a result of treatment for renal 
disease attended nephrology services. 
 
Table 28. Most common specialist services, other than hepatology, attended by living participants 
since the last round of follow-up data collection
Most common services attended Ever chronically infected Never chronically infected
 Number % Number %
Haematology 70 10.3 16 3.7
Rheumatology 39 5.8 19 4.4
Endocrinology 42 6.2 15 3.5
Physiotherapy 35 5.2 21 4.9
Psychiatry/psychology/counselling 47 6.9 5 1.2
Surgical 31 4.6 15 3.5
Cardiology 21 3.1 13 3.0
Dermatology 23 3.4 5 1.2
Dietician/nutritionist 19 2.8 9 2.1
Nephrology 20 3.0 6 1.4
Orthopaedic 16 2.4 9 2.1
Neurology 14 2.1 9 2.1
Respiratory 13 1.9 6 1.4
Obstetrics/Gynaecology 12 1.8 5 1.2
Ophthalmology 12 1.8 4 0.9
Dental 12 1.8 3 0.7
Since last follow-up, 57% (n=385) of ever chronically infected living participants and 28% (n=122) of those 
who were never chronically infected underwent one or more procedures aside from liver biopsies. The 
most common liver-related procedures were ultrasounds (37% of chronically infected living participants) 
and CT scans (6% of chronically infected living participants) (table 29). The number of biopsies being 
carried out has been decreasing in recent years. Because ultrasounds are less invasive and more 
acceptable to patients, it is likely that they are increasingly being used to monitor disease progression 
where possible (figure 11). Some of the hepatology units have also started to use fibroscans to assess liver 
elasticity.
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Table 29. Most common procedures undergone by living participants since the last round of follow-up 
data collection
Most common procedures Ever chronically infected Never chronically infected
 Number % Number %
Ultrasound (liver or liver related) 252 37.2 29 6.8
X-ray (not liver related) 135 19.9 66 15.4
Upper GI endoscopy 49 7.2 16 3.7
CT Scan (liver or liver related) 39 5.8 10 2.3
Colonoscopy/ileoscopy 23 3.4 21 4.9
Ultrasound (not liver related) 35 5.2 8 1.9
CT Scan (not liver related) 27 4.0 8 1.9
MRI (not liver related) 21 3.1 12 2.8
ECG 11 1.6 5 1.2
MRI (liver or liver related) 8 1.2 0 0.0
If health services or procedures are availed of privately and not discussed with a participant’s hepatologist 
they will not be recorded in a participant’s medical chart and will be under-represented in the database. 
Services known to be commonly attended on a private basis include counselling, physiotherapy, chiropody 
and complementary and alternative therapies.
Complementary and alternative therapies
Information recorded in the medical charts of participants indicates that 6% used one or more 
complementary or alternative therapies. The most common therapies used were herbal remedies or 
supplements (3%), acupuncture (2%), massage therapy (1%) and reflexology (1%). However, data from the 
HSE relating to the use of health services for HAA cardholders indicate very high usage of complementary 
and alternative therapies (personal communication: Michele Tait, HSE). In 2009, approximately 3,600 
complementary therapy sessions were recorded. Therapies included in this are reflexology, massage, 
aromatherapy, hydrotherapy and acupuncture. Reflexology and massage are the most commonly used. 
All of these are accessed on a private basis. In 2009, approximately 850 physiotherapy sessions were 
recorded. Both complementary therapies and physiotherapy are funded under the HAA only on the 
recommendation of the patient’s GP or consultant hepatologist.  
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Chapter 5  Discussion
The information presented in this report is based on the third round of data collection on over 1,300 
people infected with HCV through blood or blood products administered in Ireland. The database 
participants represent over three quarters of the total number of people identified as having been 
infected in this way. The collection of their medical information on a regular basis allows us to follow the 
natural history of HCV infection, their response to treatment and their use of health services. The number 
of eligible people participating in the database has continued to rise, with some previous non-responders 
now giving consent, and with the identification of small numbers of newly eligible people each year.
Viral clearance
It is estimated that between 19% and 36% of the database population had spontaneous clearance of 
HCV, depending on whether the total population includes all those with any antibody positive result or 
only those with positive confirmatory tests. This finding is in keeping with the generally accepted range 
of 55-85% for development of chronic infection.5,6 Females were significantly more likely to have cleared 
the virus by the time of their diagnosis than males. The gender bias in viral clearance is supported by a 
systematic review of 31 studies of acute HCV infection which found a mean spontaneous viral clearance 
rate of 26% and that viral clearance was significantly higher in females (42%) compared to males (20%).19
Disease progression
This is a crucial time to follow the progress of disease, as the database participants have now been 
infected for an average of 30 years and the majority are now aged over 50 years. In HCV infection, 
the association between both duration of infection and age, with fibrosis progression, has been well 
described, and it has been estimated that up to 20% of patients will progress to cirrhosis over 20-25 years 
after infection.1,9
The overall impression from this latest round of data collection is that, although there is evidence of 
progression of disease in some people, the majority of the database population, even those chronically 
infected, do not have any evidence of serious liver disease. The vast majority of those who did not 
become chronically infected have no signs of liver disease. Since baseline data collection about three 
years ago, an increase of 11-37% has been seen in the prevalence of the main liver-related outcomes 
among those chronically infected (high fibrosis scores, signs of liver disease, cirrhosis, death, liver-related 
death). The rise in HCC has been greater, but the numbers of HCC are small. The prevalence of these 
outcomes will be monitored closely in the coming years.
Cirrhosis
There has been a slight increase in the prevalence of cirrhosis, with 14% of chronically infected 
participants now having developed cirrhosis. Over a quarter of chronically infected participants with 
cirrhosis had high alcohol use. Cirrhosis was also significantly associated with infection through blood 
transfusion/renal treatment and clotting factors, rather than anti-D. The cohort of participants who were 
infected through anti-D in the 1977-79 outbreak have a low rate of cirrhosis at 9.3%, despite an average 
duration of infection of 31 years. A Canadian study looking at the prognosis of patients infected with HCV 
through receipt of contaminated blood products found that approximately 10% had developed cirrhosis 
after 20 years of infection. This study also predicted that 37% of haemophiliac patients and 23% of non-
haemophiliac patients would develop cirrhosis after 40 years of infection.28
Our method of estimating the rate of fibrosis progression was similar to that used by Poynard et al in 
a large-scale study looking at fibrosis progression in people infected with HCV.29 They estimated the 
time from infection to cirrhosis to be 24 years in people with high alcohol consumption and 42 years in 
females who were infected when less than 40 years of age and who did not have high levels of alcohol 
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consumption. Our findings were of longer periods of progression, at 27 years and 80 years respectively. 
However, as Poynard et al point out, these results should not be interpreted as meaning that progression 
to cirrhosis is universal and inevitable. Based on their estimated average rate of fibrosis progression and 
without treatment, the median expected time to cirrhosis was 30 years; 33% of patients had an expected 
median time to cirrhosis of less than 20 years and 31% will never progress to cirrhosis or will not progress 
for at least 50 years. A recent meta-analysis of a large number of published studies of HCV natural history 
reported an estimated prevalence of cirrhosis to be 16% at 20 years after infection and nearly three-fold 
higher at 30 years. The predicted estimates varied by study design, setting, population, age at infection 
and duration of infection. The progression of fibrosis appears to be non-linear with particularly high 
progression in the third decade of infection.30
HCC and deaths
Since the previous round of data collection an additional three people have developed HCC and there 
have been an additional 15 deaths, five of which were directly caused by liver disease.
Severe liver disease
We created a summary measurement of disease progression to describe those having any evidence of 
severe liver disease: 27% of those chronically infected were thus described as having severe liver disease 
compared to 2% of those who were never chronically infected. It is not possible to determine what 
proportion of this amount of liver disease is due to HCV rather than other factors which may damage the 
liver. 
The same factors were repeatedly found to be related to the poorer outcomes of chronic HCV infection 
in the database population. These were high alcohol intake, male gender, older age at the time of follow-
up, and longer duration of infection. Associations between these factors and HCV disease progression 
have been described in many other studies.1,6,9,29,31-34 Infection through blood transfusion/renal treatment 
or through clotting factors, rather than anti-D, was also related to poorer outcomes in the database 
population.
Genotype 3
The finding that participants infected with HCV genotype 3 had higher odds of severe disease than 
those with genotype 1 HCV has not been commonly reported. Although it is well established that HCV 
genotype is an important determinant of response to treatment, less evidence exists regarding an 
association between HCV genotypes and differences in the natural course of disease. The published data 
on the impact of HCV genotypes on fibrosis progression rates, development of cirrhosis, and the risk for 
HCC, have been conflicting.35 However, a recent study on a large dataset, the Swiss Hepatitis C Cohort, 
found that HCV genotype 3 was associated with accelerated fibrosis.36 There is a possible mechanism 
for genotype 3 to influence disease progression as there is a biological association between genotype 
3 and steatosis independently of BMI. Steatosis has also been found to be associated with fibrosis 
progression.37 However, it is also possible that this finding regarding genotype 3 could be explained by 
residual confounding or the potential confounding effects of another factor not included in the model. For 
instance, we could not examine the effects of BMI on disease progression in the database cohort as BMI 
data were only available for a minority of participants. In addition, it is possible that the distribution of 
co-morbidities varied by genotype and this has not been accounted for. Conflicting results were reported 
from the UK HCV Register which found that type 1 infection is associated with greater aggressiveness 
than type 2 or 3 infections, with type 1 infection being independently associated with more advanced 
stages of liver disease on biopsies carried out by the Registry.38 They also found that HCV genotype 1 
infection is more likely to be associated with spontaneous clearance than non-1 infection. 
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Alcohol
The importance of alcohol consumption deserves highlighting. Alcohol is known to be an important 
co-factor in the progression of HCV liver disease to cirrhosis and hepatocellular carcinoma.1,5,9 Alcohol use 
during therapy also adversely affects response to treatment. Safe levels of alcohol consumption are still 
unclear and even moderate levels of consumption may accelerate disease progression in some patients.5 
In the database, alcohol intake was found to be the most important factor in disease progression, with 
participants who had high alcohol intake having almost five times higher odds of having severe liver 
disease than those without. Unfortunately, although there was information about alcohol consumption 
available in the medical records of the majority of participants, in many cases there was no recent 
information recorded. Alcohol consumption is also likely to be under-reported. This may explain why, 
although the results did demonstrate a relationship between high alcohol consumption and unfavourable 
outcomes, no such relationship was seen for moderately high consumption. Given the unequivocal 
findings from the database, supported by international literature, of the association between high alcohol 
consumption and negative outcomes in HCV infected people, it is essential that information on current 
alcohol intake is available in the database. We will continue to encourage the recording of this at all 
outpatient hepatology visits. 
Overweight
Overweight is known to be a risk factor for disease progression, perhaps reflecting the higher rate of 
hepatic steatosis and steatohepatitis, a precursor to fibrosis, observed among overweight patients. The 
association between obesity and virological response to treatment is less clear-cut with conflicting results 
from different studies.39 We record body mass index (BMI) in the database wherever this information is 
available in the medical chart but to date this has been available in only a minority of cases. We hope that 
it will be possible to have body weight recorded as a routine at each clinic visit in the future so that we 
can investigate any association between overweight and disease progression or response to treatment in 
this group.
Medical conditions
Although medical conditions that are recorded in participants’ medical charts are entered into the 
database, the interpretation of these data is difficult without having a comparison group against which to 
compare the frequency of their occurrence. These conditions may be best studied by separate research 
but data contained in the database may provide the stimulus to investigate certain conditions. A health 
and lifestyle survey that was carried out on HAA card recipients in 2009 will be published later this year 
and will compare results in HCV infected people with those in the general population. 
Treatment uptake and response
The database provides interesting information on the use of and response to antiviral treatment of 
participants. Almost 41% of chronically infected participants have been treated, with significant numbers 
still commencing treatment each year. This figure is high compared to that reported in other cohorts 
where only a small sub-set of those infected and diagnosed have been treated.40 However, lack of access 
to specialist care has been found to be a factor in low levels of treatment in some settings and this would 
not apply to the database population because of their access to health services facilitated by the HAA 
scheme. By the end of 2008, 70% of genotype 2 and 3 participants have received antiviral treatment, and 
33% of genotype 1. Participants commencing treatment in recent years include greater proportions of 
genotype 1. Their response to completion of treatment will be followed with interest in the coming years.
Currently, the recommended therapy of chronic HCV infection is the combination of a pegylated 
interferon alfa and ribavirin.5,11,41 Successful response to treatment, as measured by SVR, has been 
similar in the database participants to that reported in the international literature following combination 
treatment. Large-scale clinical trials have reported SVR rates of 76-82% in genotype 3 patients and 42-46% 
in genotype 1 patients on this treatment regime.11,42,43 The treatment outcomes for database patients who 
have been treated with these regimes have been comparable at 77% and 47% respectively.
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A successful response to treatment in database participants has been associated with genotype (genotype 
2 or 3), younger age at treatment, female gender and lower fibrosis scores. This is in keeping with the 
findings of international studies.39,41 
Pre-treatment viral load
Large clinical trials have also demonstrated that, in addition to HCV genotype, pre-treatment viral load 
is a major predictor of SVR following combination treatment.41 Patients with high baseline viral loads 
>800,000 IU/ml are less likely to achieve an SVR than those with lower viral loads.39 We have not been 
able to assess this association in the database due to lack of standardisation in the quantification of viral 
loads. In the past, different laboratories have used different tests and reported results in different units 
of measurement. However, the recent adoption of international units (IU/ml) for measuring viral load by 
the relevant laboratories in Ireland will allow us in the coming years to look at the association between 
pre-treatment viral load and SVR, and between early virological response (EVR)/rapid virological response 
(RVR) and SVR, in database participants.
EVR and RVR
Early sustained suppression of HCV replication has been shown to be a good predictor of SVR. The 
likelihood that a patient will fail to achieve an SVR can be predicted by the virological response at 12 
weeks of treatment (EVR) and probably even earlier. A patient not demonstrating an EVR (a decrease in 
serum HCV RNA by 2 logs or more at treatment week 12) has a less than 3% chance of achieving SVR. Of 
patients who do show an EVR, 67% to 80% achieve an SVR.44,45
An RVR (HCV RNA undetectable at week 4 of treatment) is now emerging as another milestone in patient 
care.46 In general, RVR is a robust predictor of SVR, and studies suggest that patients infected with 
genotype 2 or 3 who attain RVR may be candidates for a shortened duration of therapy.27,47 A recent 
study has demonstrated that the ultimate response to treatment can be identified within the first 24 hours 
by a decline in viral load that is more marked in responders than non-responders.48
Clinical outcome of treatment
Although SVR is used as an indicator of successful treatment, improved clinical outcomes following 
treatment have also been demonstrated in many studies. Several large studies have suggested that 
successful treatment with pegylated interferon and ribavirin (as evidenced by SVR) may halt and even 
reverse hepatic fibrosis.49,50 SVR to treatment has also been shown to be associated with improved clinical 
outcomes, mainly prevention of liver failure, in patients with chronic HCV infection and advanced fibrosis.51 
Viral eradication is sometimes accompanied by reversal of cirrhosis, and histopathologically documented 
regression of cirrhosis has been shown to be associated with decreased disease-related morbidity and 
improved survival.52 We will continue to follow these clinical outcomes in the database population, both 
treated and untreated.
In the database participants, 22% of treatment courses with combination therapy have been stopped early 
due to side effects. Internationally, the numbers demonstrating premature withdrawal from therapy due 
to side effects are now lower than in earlier studies at 10-20%, suggesting improved understanding and 
management of adverse events.10 In the next round of data collection we plan to record the details of side 
effects leading to premature cessation of treatment.
Liver transplants
By the end of 2008, 18 of the database participants had received liver transplants. Where post-transplant 
information was available, many of them showed accelerated disease progression with fibrosis, cirrhosis 
or HCC. HCV re-infection is known to occur in almost all patients after liver transplantation and to 
lead to a more rapid course post-transplant than in immune-competent individuals.10 A large American 
study looking at post-transplant outcomes after liver transplantation found that the natural history of 
HCV cirrhosis was accelerated post-transplant. In this study, 18% (n=88) of 502 HCV infected patients 
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developed cirrhosis within 3.7 years of transplantation.53 Another study looking at survival post-transplant 
found that, of 200 patients with HCV infection who underwent liver transplantation, 95% were still alive 
after 1 year and 79% were still alive after seven years. They also found that approximately half of their 
patients experienced significant early fibrosis recurrence post-transplant.54
Focus on different groups
The participants in the National Hepatitis C Database, although all infected with HCV through 
administration of blood and blood products within Ireland, are not a homogeneous group. There are 
several sub-groups within this population, differing in their age and sex breakdown, mode of acquisition 
of HCV, co-morbidities and other factors. In analysing data by the different sub-groups, it is apparent that 
they vary also in their clinical outcomes to date and in their response to treatment. We plan to continue to 
monitor the outcomes separately in these three groups in the years ahead.
Anti-D group
In general, those infected through anti-D immunoglobulin have fared better that those infected by other 
means. In spite of having the longest average duration of infection, they have the lowest prevalence of 
serious liver-related outcomes. This may be explained by the fact that they are female, were younger 
at the time of infection, and in general they did not have co-morbidities. They also have lower alcohol 
consumption. There are two distinct anti-D groups: 1977-79 outbreak (genotype 1) and 1991-94 outbreak 
(genotype 3). Those in the smaller, more recent outbreak group, infected with genotype 3, have better 
outcomes to date, which is to be expected as they have a shorter duration of infection, and greater 
numbers have been treated and have had a successful response to treatment.
Blood transfusion/renal group
Database participants infected through blood transfusions or treatment for renal disease had the highest 
prevalence of severe liver disease despite having the shortest average duration of infection. This is likely 
to be attributable to the fact that many of them had co-morbidities; they are also older than the anti-D 
group and had a higher prevalence of high alcohol consumption. 
Blood clotting factor group
Of those infected through clotting factors, over 40% were co-infected with HIV. Those who were HIV 
positive were twice as likely to have signs of serious liver disease compared to those who were HIV 
negative. Compared with HCV mono-infected patients, co-infected patients are known to have an 
increased risk of developing cirrhosis and decompensated liver disease.55 Although the success of 
treatment of HCV and HIV co-infection with pegylated interferon and ribavirin has been demonstrated 
in several randomised trials, the overall SVR rates were lower than in patients with HCV mono-infection. 
Important predictors of response in these trials included HCV genotype, pre-treatment HCV RNA level, 
and presence of RVR and EVR.56-58 However, among database participants infected through clotting 
factors, 51% of those treated have attained an SVR, and those with HIV co-infection achieved a similar 
response to those with HCV mono-infection. Good virological outcomes to treatment in HCV/HIV 
co-infected haemophiliac patients in Ireland have been reported previously.59
Use of services
The majority of chronically infected participants have continued to attend regularly for out-patient visits. 
These hospital services and resulting referrals to other health services are provided free of charge under 
the Health (Amendment) Act 1996. As expected, those who never became chronically infected were less 
likely to have attended recently and some have been effectively discharged from their units. However, in 
analysing the database data, the models take account of duration of infection at last follow-up and age 
at last follow-up. The next round of data collection will collect information on when the patient is next 
scheduled to attend for an out-patient appointment, or whether they have been discharged or lost to 
follow-up.
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The number of biopsies being carried out has declined in recent years. Some of the hepatology units 
have started to use fibroscans (transient elastography) to quantify liver fibrosis. This is a new, non-invasive 
method that uses both ultrasound and low frequency elastic waves to assess liver elasticity.60-62 Fibroscan 
results, where available in the hepatology units, will be captured in the next round of data collection.
 
Complementary and alternative therapies
Although the database does record information about usage of complementary and alternative therapies 
where these are mentioned in patient charts, we acknowledge that this is not a reliable source of this 
information. Patients may not mention their use of these treatments to their hospital consultant or this 
information may not be recorded in the chart. The figure of 6% of participants using such therapies is 
likely to be a significant under-estimate, given the usage quoted under the HAA scheme, and information 
from other studies. According to a recent study carried out in Ireland, and in line with international 
studies, the use of complementary therapy is high, and increasing, in the general population in Ireland 
with an increase from 20% to 27% between 1998 and 2002.63 Numerous studies indicate that most 
complementary and alternative therapy users do not attend practitioners and are more likely to self 
prescribe.63 The health and lifestyle survey carried out in 2009, mentioned above, is likely to provide more 
useful information on HAA cardholders use of complementary and alternative therapies.
Conclusion
The National Hepatitis C Database project has progressed in both participation rate and quality of data 
since its establishment six years ago. The ongoing support of participants, support groups and health 
professionals is essential to its success. Eligible people who have not yet participated may join at any time 
through their hepatology unit.
The regular collection of data from the hospital records of participants will continue. We would encourage 
hepatology unit staff to record body weight/BMI and alcohol consumption information as a routine at 
clinic visits. In the next round of data collection, additional information, where available, will be collected 
on: insulin resistance, steatosis, fibroscans, details of adverse effects of treatment, both starting and 
finishing treatment doses, and clinic follow-up/discharge status of patients. We look forward to carrying 
out more detailed analysis of viral load data, recorded now in a standardised format, before, during and 
after treatment.
The data in the database are available for use by researchers and by the participating hepatology units. 
The policy and procedures for accessing information contained in the database are outlined in a document 
which is available on the database website or through the project team at HPSC. All publications based 
on data from the database must acknowledge the National Hepatitis C Database and the participating 
hepatology units.
We welcome any comments and suggestions that participants, health professionals or other interested 
people may have on ways in which we could improve the database and the use of the information 
contained in it.
- 57 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
References
1. Poynard T, Yeun M-F, Ratziu V, Lai CL. Viral Hepatitis C. Lancet 2003;362:2095-8.
2. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in 
collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium, J Viral Hepat 1999;6;35-47.
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-S29. 
4. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52. 
5. NIH consensus statement on management of hepatitis C:2002 June 10-12;19(3):1-46.
6. Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int 2009;29(s1):89-99.
7. Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection 
from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-33. 
8. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U, for the East German Hepatitis C Study Group. Low 
frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year 
multicenter study. Hepatology 2000;32:91-6.
9. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 
2007;42:513-21.
10. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and 
complications. Gut 2006;55(9):1350-9.
11. National Institute for Clinical Excellence. NHS. Interferon alpha (pegylated and non-pegylated) and 
ribavirin for the treatment of chronic hepatitis C. Technology appraisal 75. London: NICE; 2004.
12. McGee H, Hickey A, Smith M, Byrne M. Review of health services available for persons who 
contracted hepatitis C through the administration within the state of blood and blood products. 
Dublin: Consultative Council on Hepatitis C, Department of Health and Children; 2000.
13. Health Protection Surveillance Centre. National Hepatitis C Database. Baseline Report. October 2007. 
Available at: http://www.hpsc.ie/hpsc/A-Z/HepatitisHIVAIDSandSTIs/HepatitisC/HepatitisCDatabase/
BaselineandFollow-upReports/
14. Health Protection Surveillance Centre. National Hepatitis C Database. Follow Up Report. 
February 2009. Available at: http://www.hpsc.ie/hpsc/A-Z/HepatitisHIVAIDSandSTIs/HepatitisC/
HepatitisCDatabase/BaselineandFollow-upReports/
15. Knodell RG, Ishak KG, Black WC, Chent TS, Craig R, Kaplowitz N, et al. Formulation and application of 
a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. 
Hepatology 1981;1(5):431-5.
16. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging 
of chronic hepatitis. J Hepatol 1995;22(6):696-9.
17. Desmet V, Gerber M, Hoofnagle J, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, 
grading and staging. Hepatology 1994;19(6):1513-1520.
18. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-4.
19. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A 
systematic review of longitudinal studies. J Viral Hepat 2006;13(1):34-41.
20. Jauncey M, Micallef JM, Gilmour S, Amin J, White PA, Rawlinson W, et al. Clearance of hepatitis C 
virus after newly acquired infection in injection drug users. JID 2004;190:1270-4.
21. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses 
persist and humoral responses decrease two decades after recovery from a single-source outbreak of 
hepatitis C. Nature Medicine 2000;6:578-82. 
22. Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, et al. Virus-
specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat 2002;9:429-37.
23. Wawrzynowicz-Syczewska M, Kubicka J, Lewandowski Z, Boron-Kaczmarska A, Radkowski M. Natural 
history of acute symptomatic hepatitis type C. Infection 2004;32:138-43.
24. Finlay TA. Report of the Tribunal of Inquiry into the Blood Transfusion Service Board. Dublin: 
Government Publications; 1997.
- 58 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
25. Department of Health and Children. Strategic Task Force on Alcohol. Second report. Sept 2004. 
Dublin: Health Promotion Unit, Department of Health and Children.
26. Ong S, Codd MB, Coughlan M, O’Herlihy C. Prevalence of hysterectomy in Ireland. Int J Gynaecol 
Obstet. 2000;69(3):243-7.
27. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement 
on the management of hepatitis C. Gastroenterology 2006;130:225-30.
28. Thein HH, Yi Q, Heathcote EJ, Krahn MD. Prognosis of hepatitis C virus-infected Canadian post-
transfusion compensation claimant cohort. J Viral Hepat 2009 Nov;16(11):802-13.
29. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in participants with chronic 
hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997;349:825-32. 
30. Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic 
hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-31.
31. Harris HE, Ramsay ME, Andrews N, Eldridge KP; HCV National Register Steering Group. Clinical 
course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002;324:450-3.
32. Mohsen AH. Trent HCV study group. The epidemiology of hepatitis C in a UK health regional 
population of 5.12 million. Gut 2001;48:707-13.
33. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, et al. 45-Year follow-up 
of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
34. Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C 
virus infection. J Viral Hepat 2003;10(4):285-93.
35. Zeuzem S. Forewarned is forearmed. J Hepatol 2009;51:626-7. 
36. Bochud P-Y, Cai T, Overbeck K, Bochud M, Dufour J-F, Mullhaupt B, et al. Genotype 3 is associated 
with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655-66.
37. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al. Steatosis affects chronic 
hepatitis C progression in a genotype specific way. Gut 2004;53:406-12.
38. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo C-G, Ramsay ME, et al. Does the clinical outcome 
of hepatitis C infection vary with the infecting hepatitis C virus type? J Virol Hepat 2007;14:213-220. 
39. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with 
chronic hepatitis C: who responds less well? Ann Int Med 2004;140:370-81. 
40. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob 
Chemother 2010;65:1327-9. 
41. Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD Practice Guidelines. Diagnosis, management, 
and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374. 
42. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon 
alpha-2b plus ribavirin 2001 compared with interferon alpha-2b plus ribavirin for initial treatment of 
chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65. 
43. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alpha-2a 
plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82. 
44. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to 
treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 
2003;38(3):645-52. 
45. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, et al. Predicting sustained 
virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. 
J Hepatol 2005;43(3):425-33.
46. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of 
chronic hepatitis C. CID 2008;46:78-84.
47. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b 
or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93. 
48. Devitt E, Lawless MW, Sadlier D, Browne JA, Walsh C, Crowe J. Early viral and peripheral blood 
mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24h. Eur J 
Gastroenterol Hepatol 2010 Jul 13. [Epub ahead of print]
- 59 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
49. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon 
alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 
2004; 39:333-42. 
50. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated 
interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 
2002;122:1303-13.
51. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann P, Zeuzem S, et al. Sustained virologic 
response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern 
Med 2007;147:677-84. 
52. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, et al. Brief 
communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann 
Intern Med 2008;149:399-403. 
53. Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, et al. The natural history of hepatitis C 
cirrhosis after liver transplantation. Liver Transpl 2009;15(9):1063-71.
54. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, et al. Natural history of 
post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 
2009;15(12):1872-81.
55. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency 
virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-
9.
56. Dhillon R, Rossi S, Herrine SK. Pegylated interferon 2a and 2b in combination with ribavirin for the 
treatment of chronic hepatitis C in HIV infected patients. Ther Clin Risk Manag 2008;4(4):789-96.
57. Carrat F, Bani-Sadr F, Pols S, Rosenthal E, Lunel-Fabiani F, Benzekiri A, et al; ANRS HCO2 RIBAVIC 
study team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic 
hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48. 
58. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al; APRICOT 
study group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection in HIV-infected 
patients. N Engl J Med 2004;351:438-50.
59. Kevans D, Farrell G, Hopkins S, Mahmud N, White B, Norris S, et al. Haematological support during 
peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes. Haemophilia 
2007:13:593-8.
60. Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, et al. Assessment of liver fibrosis by 
transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. 
CID 2009;48:963-72. 
61. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of 
transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in hepatitis C. 
Gastroenterology 2005;128:343-50. 
62. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new 
non-invasive method for assessment of hepatic fibrosis. Ultrasound Med Bio 2003;29:1705-13. 
63. Fox P, Coughlan B, Butler M, Kelleher C. Complementary alternative medicine (CAM) use in Ireland: A 
secondary analysis of SLAN data. Complement Ther Med 2010;18(2):95-103.
- 60 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
Glossary of definitions, terms and 
abbreviations
Definitions
Case of hepatitis C for the purpose of this database
Any patient with one or more positive test results for hepatitis C, including positive RNA (PCR), line-
immunoassay (RIBA/INNO-LIA) or EIA results, indeterminate line-immunoassay results and weak positive 
EIA results.
Confirmed positive case of hepatitis C
Any patient who had at least one positive RNA (PCR) result or at least one positive line-immunoassay 
(RIBA/INNO-LIA) result.
Ever hepatitis C RNA positive (PCR positive)
Any patient who had at least one positive RNA (PCR) result
Definition of alcohol use in excess of recommended limits
More than 14 units (standard drinks) per week for females
More than 21 units (standard drinks) per week for males
A standard drink in Ireland today equals 10gms of alcohol and is equal to a half pint of beer or a single 
measure of spirits or a small glass of wine. The limits of 14 and 21 standard drinks (spread out over the 
week) for women and men respectively are used as a general guide for low risk drinking (Strategic Task 
Force on Alcohol. Second Report. Sept 2004).
Terms
Anti-D
Antibodies against rhesus D antigens. A small amount of the baby’s blood can enter the mother’s 
circulation during pregnancy, or larger amounts can enter during delivery. If the mother is negative for 
rhesus proteins and the baby is rhesus positive, the mother produces antibodies against the rhesus D 
antigens. These antibodies can pass through the placenta and damage the baby. The risk of disease is 
higher with subsequent pregnancies with rhesus positive babies. Anti-D immunoglobulin given during or 
after pregnancy prevents this.
Ascites
The accumulation of fluid in the spaces between tissues and organs in the abdominal cavity.
Autoantibody tests
Autoantibody tests detect antibodies, which normally fight infections and other foreign substance within 
the body, but are mistakenly attacking the body’s own cells, tissues or organs.
Blood clotting disorders (as used in this report)
Inherited blood disorders in which there is a defect in a factor essential for the clotting mechanism of the 
blood. These include haemophilia A (deficient in factor VIII), haemophilia B (deficient in factor IX), von 
Willebrand disease (deficient in von Willebrand factor) and deficiencies of factors V, VII or X.
Cirrhosis
Widespread replacement of liver tissue by fibrotic scar tissue and regenerative nodules, leading to 
progressive loss of liver function.
Complementary and alternative medicine
A group of diverse medical and health care systems, practices and products that are not currently 
considered to be part of conventional medicine. The term includes herbalism, aromatherapy, homeopathy, 
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acupuncture, massage and reflexology. Complementary medicine is used together with conventional 
medicine. Alternative medicine is used in place of conventional medicine. 
Confidence interval for an odds ratio
The width of a confidence interval provides a range of plausible values for the odds ratio in the population 
from which the data were sampled and gives an idea of the degree of confidence about the accuracy of an 
odds ratio. 
Database
A systematically arranged collection of computer data, structured so that it can be automatically retrieved 
or manipulated.
Early Virological Response (EVR)
Undetectable HCV RNA (< 50 IU/mL) by qualitative PCR or a ≥2 log drop in HCV RNA at week 12 by 
quantitative PCR
Extrahepatic manifestations of hepatitis C
Outside of, or unrelated to, the liver. Extrahepatic manifestations associated with hepatitis C include 
cryoglogulinaemia syndrome, glomerulonephritis, neuropathy, lymphoma, Sjögren syndrome, porphyria 
cutanea tarda, diabetes.
Fibrosis
Liver fibrosis refers to the accumulation of tough fibrous scar tissue in the liver.
Genotype testing
Hepatitis C genotype tests are used to determine which of the genetically distinct types of hepatitis C virus 
are present in the patient’s blood. Hepatitis C genotype is important in predicting response to anti-viral 
therapy. 
Health Amendment Act (HAA) card
The HAA card is given to people who contracted hepatitis C from the administration within the state of 
blood or blood products. They are entitled to a range of services under the Health (Amendment) Act 1996. 
Hepatic encephalopathy
Neuropsychiatric abnormality in the setting of liver failure. It is caused by toxic substances, which are 
normally removed by the liver, travelling in the blood to the brain.
Hepatitis C EIA (Enzyme Immunoassay)/ELISA (Enzyme-Linked Immunosorbent assay)
An assay that detects antibodies to specific hepatitis C antigens in a patient’s blood. The hepatitis C EIA 
test is usually used as an initial screening test for hepatitis C antibodies.
Hepatitis C PCR test (Polymerase Chain Reaction)
Test used to detect the presence of hepatitis C virus RNA (genetic material). A positive PCR result indicates 
an active infection with replicating virus.
Hepatocellular carcinoma (HCC)
Primary malignancy (cancer) of the liver.
Hepatomegaly
Enlarged liver.
Liver biopsy
A liver biopsy is a medical procedure involving the removal of a small piece of liver using a special needle. 
This is then examined under a microscope for signs of liver abnormality.
Liver function tests (LFTs)
Liver function tests are a group of blood tests which provide information about how the patient’s liver is 
functioning and may act as indicators of liver injury.
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Mean (average)
The mean is a measure of central value that is used when values are normally distributed. The mean is 
calculated by dividing the sum of all the observations by the total number of observations. 
Median
The median is a measure of central value that is used when values are not normally distributed (skewed 
to one side). The median is obtained by arranging observations from lowest value to highest value and 
picking the middle value (divides the observations in half).
Meta-analysis
A meta-analysis combines the result of several studies on a particular topic to give an overall summary 
measure of effect.
Multivariate logistic regression
Logistic regression is used to determine if the presence of, or level of, other characteristics affect the 
likelihood of a specific outcome of interest occurring. In a multivariate logistic regression model, each 
factor in the model is adjusted for the effect of the other factors on the outcome.
Odds ratio
The odds ratio is a measure of the odds of an event occurring in one group divided by the odds of it 
occurring in another group. An odds ratio of 1 indicates that the event is equally likely in both groups.
Oesophageal varices
Abnormally dilated and lengthened sub-mucosal veins in the oesophagus. These are usually a consequence 
of portal hypertension and may bleed.
Portal hypertension
High blood pressure in the portal vein that carries blood from the digestive tract to the liver. The most 
common cause is cirrhosis. Consequences can include ascites, hepatic encephalopathy, oesophageal 
varices and splenomegaly.
P-value
In statistics, a result is deemed significant if it is unlikely to have occurred by chance. The p-value is the 
probability of obtaining a result at least as extreme as the result obtained in the analysis, by chance alone. 
A p-value of 0.05 indicates that there was a 5% (or 1 in 20) chance of obtaining the result by chance alone. 
If you are comparing the occurrence of a characteristic in two groups, a low p-value (<0.05) indicates that 
it is likely that there is a true difference in the value of, or odds of the occurrence of a characteristic in the 
two groups.
Rapid Virological Response (RVR)
HCV RNA undetectable at week 4 of treatment
Recombinant immunoblot assay (RIBA)
An additional test for hepatitis C specific antigens in a patient’s blood. RIBA tests are usually performed 
after a positive EIA result and are used to confirm the presence of antibodies to the hepatitis C virus. A 
positive RIBA result is generally considered confirmation that a patient has been infected with hepatitis C, 
but cannot differentiate between past infection and current infection.
Renal
The term renal refers to the kidney.
Sicca/Sjögren’s syndrome 
A chronic inflammatory disease that is characterized by dryness of mucous membranes especially 
of the eyes and mouth and by infiltration of the affected tissues by immune cells. There is a strong 
epidemiological association between Sjögren’s syndrome and hepatitis C infection.
Splenomegaly
Enlarged spleen.
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Sustained virological response (SVR)
The absence of detectable hepatitis C RNA in the serum as shown by a qualitative hepatitis C RNA assay 
with lower limit of detection of 50 IU/ml or less at 24 weeks after the end of treatment. 
Abbreviations
ALT Alanine aminotransferase (a liver enzyme)
Anti-HCV Antibody to hepatitis C virus
EIA Enzyme immunoassay, a screening test for hepatitis C
EVR Early Virological Response
HAA Health (Amendment) Act
HCV Hepatitis C virus
HIV Human immunodeficiency virus
HPSC  Health Protection Surveillance Centre, formerly known as the National Disease    
Surveillance Centre
HSE Health Service Executive
IBTS  Irish Blood Transfusion Service, formerly known as the Blood Transfusion Service   
Board
NDSC  National Disease Surveillance Centre, now known as the Health Protection    
Surveillance Centre
NICE National Institute for Clinical Excellence
PCR Polymerase chain reaction
RIBA Recombinant immunoblot assay, a more specific hepatitis C test
RNA Ribonucleic acid
RVR Rapid Virological Response
SVR Sustained virological response 
WHO World Health Organization
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Professor John Hegarty, St Vincent’s University Hospital (Alternate: Prof Suzanne Norris, St James’s 
Hospital)
Ms Lara Hynes, Department of Health and Children
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Dr Lelia Thornton, Health Protection Surveillance Centre
Ms Noeleen White, Positive Action
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Appendix C Data collection form for second year of follow-up
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Appendix D Biopsy scoring
Fibrosis scoring systems
Score
Original HAI or 
Knodell15
Modified HAI or Modified 
Knodell or Ishak16 or 
Desmet17
Scheuer18
International group of  
Hepatopathologists
0 No fibrosis No fibrosis None No fibrosis
1 Fibrosis portal 
expansion
Fibrosis expansion of some 
portal areas, with or without 
short fibrous septa
Enlarged, fibrotic 
portal tracts
Fibrous portal expansion
2 Fibrosis expansion of most 
portal areas, with or without 
short fibrous septa
Periportal or 
portal-portal 
septa with intact 
architecture
Portal septa with normal 
vascular relationships
3 Bridging fibrosis 
(portal-portal or 
portal-central 
linkage)
Fibrosis expansion of most 
portal areas, with occasional 
portal to portal bridging
Fibrosis with 
architectural 
distortion but no 
obvious cirrhosis
Distorted structure or 
incomplete cirrhosis (focal 
nodules)
4 Cirrhosis Fibrosis expansion of portal 
areas, with marked bridging 
(portal to portal as well as 
portal to central)
Probable or 
definite cirrhosis
Cirrhosis, probable or definite
5 Marked bridging with 
occasional nodules (incomplete 
cirrhosis)
6 Cirrhosis, probable or definite
The grade of inflammation on biopsy was categorised as:Normal, mild inflammation, moderate 
inflammation or severe inflammation
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Appendix E Contact Information
Support Groups
Positive Action
56 Fitzwilliam Square, Dublin 2. Tel: 01-676 2853, Fax: 01-662 0009
Transfusion Positive
3 Clanwilliam Square, Dublin 2. Tel: 01-639 8855. Fax: 01-639 8856
Irish Haemophilia Society
First Floor, Cathedral Court, New St, Dublin 8. Tel:01-657 9900, Fax: 01-657 9901, 
Email: info@haemophilia.ie, Website: www.haemophilia-society.ie
Irish Kidney Association
Donor House, Block 43a Park West, Dublin 12. Tel: 01-620 5306, Fax: 01-620 5366, Locall: 1890-543 639, 
E-mail: info@ika.ie, Website: www.ika.ie
Specialist Centres
Beaumont Hospital
Hepatology Unit, Beaumont Road, Dublin 9. Tel: 01-809 2220/01-809 3000
Mater Misericordiae University Hospital
Hepatology Unit, 55 Eccles St., Dublin 7. Tel:01-803 2048/01-803 2000
St James’s Hospital
Hepatology Unit, James’s St., Dublin 8. Tel: 01-410 3417/01-410 3000
St Vincent’s University Hospital
Hepatology Unit, Elm Park, Dublin 4. Tel: 01-209 4248/01-269 4533
Our Lady’s Children’s Hospital
Hepatology Unit, Crumlin, Dublin 12. Tel: 01-409 6742/01-409 6100          
 
Cork University Hospital
Hepatology Unit, Wilton, Cork. Tel: 021 492 2274/021-454 6400
University College Hospital
Hepatology Unit, Newcastle Road, Galway. Tel: 091-544 370/091-524 222
St Luke’s Hospital
Hepatology Unit, Kilkenny. Tel: 056-778 5329/056-778 5000
Liaison Officers
HSE Dublin North East
Dublin NW/N
Mr Larry Bathe, Health Service Executive, Mill Lane, Palmerstown, Dublin 20.  Tel: 01 620 1758
Cavan, Louth, Meath and Monaghan
Ms Barbara Leech, Health Service Executive, Primary Care Unit, Railway Street, Navan, Co Meath.  
Tel: 046 907 6451
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HSE Dublin/Mid Leinster 
Dublin SW/W/S/Kildare Wicklow
Ms Anne Tiernan/Ms Valerie Whelan, Health Service Executive, Primary Care Unit, Block E, Westland Park, 
Nangor Road, Dublin 12. Tel: 01  460 9671
Dublin SE/Dun Laoghaire/Bray/Wicklow
Mr John Fennell, Health Service Executive, Civic Centre, Main Street, Bray, Co Wicklow. Tel: 01 274 4257
Laois, Longford, Offaly, Westmeath
Ms Elaine Barry, Primary Care Unit, Health Service Executive,, Springfield, Mullingar, Co Westmeath. Tel: 
044 938 4429
HSE West  
Clare/Limerick/Tipperary North
Mr Michael Griffin, Primary Care Unit Manager, Health Service Executive, Ballycumin Avenue, Raheen 
Business Park, Limerick. Tel: 061 464 004
Leitrim/Sligo/Donegal
Ms Phil Mulligan/Ms Sadie Flanagan, Community Care Service, Health Service Executive, Iona Office Block, 
Main Street, Ballyshannon, Co Donegal. Tel: 071 9834000
Galway/Mayo/Roscommon
Mr Richard Broderick, Health Service Executive Primary Care Unit, Merlin Park Regional Hospital, Galway. 
Tel: 091-775673
HSE South 
Carlow/Kilkenny/Tipperary South/Waterford/Wexford
Mr Cathal O’Reilly/Ms Breda Aylward, Health Service Executive, Lacken, Dublin Rd, Kilkenny. Tel: 056-778 
4113
Cork/Kerry
Mr Donal Murphy, Primary Care Unit, 26/27 South Mall, Cork. Tel: 021 492-1872/ 021-492 1871
For all queries that cannot be resolved at local level and within the hospital services:
Ms Michele Tait, Health Service Executive, Mill Lane, Palmerstown, Dublin 20. Tel: 01 620 1750
 
Relevant National Agencies
Health Protection Surveillance Centre,
25-27 Middle Gardiner St, Dublin 1. Tel: 01-8765300. Email: hcvdatabase@hpsc.ie
Website: www.hpsc.ie, Database website: www.hcvdatabase.ie
National Centre for Hereditary Coagulation Disorders (NCHCD)
St James’s Hospital, James’s St., Dublin 8. Tel: 01-416 2141
Irish Blood Transfusion Service
National Blood Centre, James’s St., Dublin 8. Tel: 01-432 2800
National Virus Reference Laboratory
UCD, Belfield, Dublin 4. Tel: 01-716 1323
Consultative Council on Hepatitis C
2nd Floor HSE Offices, Mill Lane, Palmerstown, Dublin 20. Tel: 01-620 1708
Email: cchepc@health.irlgov.ie, Website: http://www.consultativecouncilonhepc.ie/
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h
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pi
ta
l m
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co
rd
s 
of
 p
eo
pl
e 
w
h
o 
h
av
e 
ag
re
ed
 t
o 
ta
ke
 p
ar
t 
or
 t
h
os
e 
w
h
o 
h
av
e 
di
ed
. T
h
er
e 
is
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o 
di
re
ct
 
co
n
ta
ct
 w
it
h
 p
at
ie
n
ts
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n
d 
ad
dr
es
se
s 
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e 
n
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 re
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ed
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h
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da
ta
ba
se
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 p
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f 
th
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e 
w
h
o 
ar
e 
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 t
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pa
rt
ic
ip
at
e.
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h
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 p
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pa
ti
on
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at
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 b
u
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h
ig
h
er
 p
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pa
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at
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 b
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te
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 p
eo
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h
ty
 fi
ve
 p
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ta
 c
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le
ct
io
n
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n
d 
h
av
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u
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ld
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ti
ci
pa
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, c
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se
n
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h
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u
n
it
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 c
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 c
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se
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 c
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 c
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l c
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 d
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m
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ra
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 d
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re
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 d
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 c
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at
m
en
t 
fo
r h
ep
at
it
is
 C
, i
f r
ec
om
m
en
de
d 
by
 y
ou
r d
oc
to
r
• 
D
ec
re
as
e 
or
 g
iv
e 
up
 a
lc
oh
ol
 
• 
H
ea
lt
hy
 w
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at
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 d
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 c
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 c
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at
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 p
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at
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n
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ge
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D
at
ab
as
e 
po
pu
la
ti
on
• 
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%
 o
f 
da
ta
ba
se
 p
ar
ti
ci
pa
n
ts
 a
re
 w
om
en
, d
u
e 
to
 
th
e 
la
rg
e 
n
u
m
be
r 
in
fe
ct
ed
 w
it
h
 h
ep
at
it
is
 C
 t
h
ro
u
gh
 
co
n
ta
m
in
at
ed
 a
n
ti
-D
, 7
87
 o
f 
w
h
om
 a
re
 in
cl
u
de
d 
in
 t
h
e 
da
ta
ba
se
 (fi
gu
re
 1)
• 
 O
ve
r 
h
al
f 
of
 p
ar
ti
ci
pa
ti
n
g 
m
en
 a
re
 h
ae
m
op
h
ili
ac
s 
w
h
o 
w
er
e 
in
fe
ct
ed
 t
h
ro
u
gh
 c
on
ta
m
in
at
ed
 c
lo
tt
in
g 
fa
ct
or
s 
(fi
gu
re
 1)
• 
 Th
e 
av
er
ag
e 
ag
e 
at
 fo
llo
w
 u
p 
da
ta
 c
ol
le
ct
io
n
 w
as
 5
6
 
ye
ar
s 
fo
r 
w
om
en
 a
n
d 
46
 y
ea
rs
 fo
r 
m
en
• 
 O
n
 a
ve
ra
ge
, w
om
en
 h
ad
 b
ee
n
 in
fe
ct
ed
 fo
r 
29
 y
ea
rs
 a
n
d 
m
en
 fo
r 
22
 y
ea
rs
 w
h
en
 t
h
e 
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llo
w
 u
p 
da
ta
 w
as
 c
ol
le
ct
ed
• 
 46
%
 o
f 
th
os
e 
w
h
o 
ar
e 
st
ill
 a
liv
e 
re
m
ai
n
 h
ep
at
it
is
 C
 P
C
R 
po
si
ti
ve
 a
n
d 
54
%
 n
o 
lo
n
ge
r 
te
st
 p
os
it
iv
e 
fo
r 
ci
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u
la
ti
n
g 
vi
ru
s 
(fi
gu
re
 2
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A
lc
oh
ol
 c
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su
m
pt
io
n
• 
 In
fo
rm
at
io
n
 o
n
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lc
oh
ol
 c
on
su
m
pt
io
n
 w
as
 in
fr
eq
u
en
tl
y 
re
co
rd
ed
  e
xc
ep
t 
at
 t
h
e 
fi
rs
t 
vi
si
t 
• 
 12
%
 o
f 
pa
ti
en
ts
 re
po
rt
ed
 m
od
er
at
el
y 
h
ig
h
 o
r 
h
ig
h
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co
h
ol
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ke
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 M
en
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er
e 
m
u
ch
 m
or
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el
y 
to
 re
po
rt
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co
h
ol
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n
su
m
pt
io
n
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gu
re
 3
)
• 
 H
ig
h
 a
lc
oh
ol
 in
ta
ke
 w
as
 fo
u
n
d 
to
 b
e 
as
so
ci
at
ed
 w
it
h
 
se
ve
re
 li
ve
r 
di
se
as
e 
- 6
2%
 o
f 
PC
R 
po
si
ti
ve
 p
at
ie
n
ts
 w
it
h
 
h
ig
h
 a
lc
oh
ol
 in
ta
ke
 h
ad
 s
ev
er
e 
liv
er
 d
is
ea
se
, c
om
pa
re
d 
to
 2
2%
 o
f 
th
os
e 
w
h
o 
re
po
rt
ed
 m
od
er
at
el
y 
h
ig
h
 a
lc
oh
ol
 
in
ta
ke
 o
r 
al
co
h
ol
 c
on
su
m
pt
io
n
 w
it
h
in
 re
co
m
m
en
de
d 
lim
it
s
 Si
gn
s 
of
 li
ve
r 
di
se
as
e
• 
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8 
da
ta
ba
se
 p
ar
ti
ci
pa
n
ts
 (1
2%
) h
ad
 c
lin
ic
al
 s
ig
n
s 
of
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ri
ou
s 
liv
er
 d
is
ea
se
• 
 PC
R 
po
si
ti
ve
 p
at
ie
n
ts
 (1
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) w
er
e 
m
or
e 
lik
el
y 
to
 h
av
e 
se
ri
ou
s 
liv
er
 d
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ea
se
 t
h
an
 P
C
R 
n
eg
at
iv
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r 
vi
ru
s 
u
n
de
te
ct
ab
le
) p
at
ie
n
ts
 (1
%
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C
ir
rh
os
is
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7 
pa
ti
en
ts
 h
ad
 d
ev
el
op
ed
 c
ir
rh
os
is
 o
f 
th
e 
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er
 b
y 
la
te
st
 fo
llo
w
 u
p
• 
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3 
w
er
e 
PC
R 
po
si
ti
ve
 (1
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 o
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PC
R 
po
si
ti
ve
 p
at
ie
n
ts
) a
n
d 
4 
h
ad
 n
o 
PC
R 
re
su
lt
s 
in
 t
h
ei
r 
ch
ar
ts
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 C
ir
rh
os
is
 w
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 m
or
e 
co
m
m
on
 in
 p
at
ie
n
ts
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it
h
 h
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h
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co
h
ol
 c
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su
m
pt
io
n
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en
ts
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it
h
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ir
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os
is
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 h
ig
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 c
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os
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 p
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 m
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C
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po
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ti
ve
 p
at
ie
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 b
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h
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os
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, m
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 c
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 c
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h
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h
ep
at
it
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 re
co
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h
ei
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ch
ar
ts
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ot
 k
n
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 t
h
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en
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ge
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da
ta
ba
se
 p
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n
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h
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h
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 d
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n
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h
e 
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n
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u
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at
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at
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 d
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 c
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 d
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 D
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at
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 d
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 c
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ra
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n
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 re
ce
n
tl
y 
se
n
t 
a 
h
ea
lt
h
 a
n
d 
lif
es
ty
le
 
qu
es
ti
on
n
ai
re
 t
o 
al
l H
A
A
 c
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 c
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 c
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 d
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w
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, b
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 t
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 c
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